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ABSTRACT 
Bovine viral diarrhoea virus (BVDV) is an important pathogen that causes infectious 
disease of cattle worldwide and results in significant economic losses. Vaccination 
has long been used as a tool for control of BVDV but inadequacies of existing 
vaccines have hampered eradication efforts. Attempts to develop sub-unit vaccines 
have focused on the structural envelope protein E2, which is a dominant target of 
neutralising antibodies and as well as CD4 T cell responses. This study aimed to 
rationally address the development of more efficacious vaccines by characterising 
the kinetics and specificity of T cell responses to a BVDV type 1 peptide library in 
calves rendered immune to BVDV following recovery from experimental infection. 
Upon identification of E2 and NS3 as the dominant targets of CD4 T cell responses, 
we assessed whether T cells induced by one virus genotype were capable of 
responding to a heterologous virus genotype and to identified E2 and NS3 as targets 
of genotype-specific and genotype transcending responses, respectively. This finding 
strengthened the argument for inclusion of both antigens in a subunit vaccine 
formulation. A nanoparticulate formulation of E2 and NS3 adjuvanted with poly(I:C) 
was shown to induce protective responses comparable to a commercial available 
BVDV vaccine in a vaccination and challenge experiment. It is hoped that the data 
generated will have implications for the design of improved vaccines against BVD. 
 
 
 
 
 
 
 
 
 
©Victor Riitho Njeri 
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1.1 BOVINE VIRAL DIARRHOEA VIRUS 
Bovine viral diarrhoea virus (BVDV) represents a group of enveloped, single-
stranded, positive-sense RNA viruses of the genus Pestivirus in the family 
Flaviviridae, which are closely related to classical swine fever virus (CSFV) and 
ovine border disease virus (BDV) species (Simmonds et al., 2011). BVDV is divided 
into two antigenically and genetically distinct species, BVDV-1 and BVDV-2 
(Ridpath et al., 1994). Two biotypes exist in both species, noncytopathic (ncp) and 
cytopathic (cp), based on the effect of the virus on cells in culture (Zhang et al., 
1996). BVDV-1 is further divided into at least 12 subgenotypes (BVDV-1a to l) 
(Vilcek et al., 2001) while BVDV-2 is divided into two subgenotypes (BVDV-2a and 
b) (Flores et al., 2002). More recently, atypical bovine pestiviruses have been 
discovered that have a sister phylogenetic relationship to BVDV-1 and BVDV-2 and 
have been proposed as a third species, BVDV-3 (Liu et al., 2009c). 
The BVDV virion consists of a 40-60nm-diameter particle made up of a central 
icosahedral capsid, enclosing genomic RNA, surrounded by a lipid bilayer envelope. 
The genome is approximately 12.3kb in length with 5’ and 3’ untranslated regions 
(UTR) bracketing a single open reading frame (ORF). The uncapped 5’UTR is 
highly conserved and consists of tertiary structures that make up an internal 
ribosomal entry site (IRES) required for initiation of translation (Pestova and Hellen, 
1999) while the 3’ UTR, like in other pestivirus genomes, terminates in a short 
polycytosine (C) tract. The 3’ UTR is known to contain conserved structural 
elements thought to be important for minus-strand initiation and replication (Yu et 
al., 1999). The ORF encodes a polyprotein of about 4000 amino acids which is co- 
and post-translationally processed by host and viral proteases into 11 or 12 viral 
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proteins, including four structural proteins (C, E
rns
, E1 and E2) and seven or eight 
non-structural (NS) proteins (N
pro
, p7, NS2-3 (further cleaved to NS2 and NS3 in 
cytopathic virus), NS4A, NS4B, NS5A, and NS5B) (Meyers and Thiel, 1996) as 
shown in Figure 1.1.  
The conserved capsid, C, protein forms the virion nucleocapsid, while the viral 
envelope is made up of E
rns
, E1 and E2 glycoproteins. p7 is a small protein of 
unknown function that is vital for production of viable virus but is neither associated 
with the virion structure nor necessary for RNA replication (Harada et al., 2000). 
Cleavage between E2 and p7, like other structural proteins, is by host cellular 
proteases (signal peptide peptidase and signal peptidases) and has been reported to be 
incomplete, resulting in p7, E2 and E2-p7 proteins. Unlike p7 and E2, E2-p7 is not 
essential for the generation of infectious virus. E
rns
 is an envelope glycoprotein with 
intrinsic RNase activity (Schneider et al., 1993) and is unique to pestiviruses. It has 
the ability to translocate across the plasma membrane, which suggests that it may 
have a role in virus entry into target cells (Fetzer et al., 2005). 
N
pro
, the N-terminal self-cleaving cysteine protease (Rumenapf et al., 1998), 
like E
rns
, is  unique to pestiviruses. NS2/3 protein is a highly conserved protein with 
multiple enzymatic functions (N-terminal serine protease (Bazan and Fletterick, 
1989), C-terminal RNA helicase (Gorbalenya et al., 1989) and NTPase (Gu et al., 
2000)) and is known to cleave both itself and downstream NS proteins from the viral 
polyprotein employing NS4A protein as a cofactor (Tautz et al., 2000). NS5B is an 
RNA-dependent RNA polymerase that together with NS4B, the zinc-binding 
phosphorylated NS5A and unknown host factors, make up the viral replicase 
complex in association with intracytoplasmic membranes (Zhong et al., 1998). 
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Figure 1.1. The virion morphology and genome organisation of BVDV and other 
pestiviruses. Electron micrographs show pestiviruses as spherical enveloped viruses 
with genomic RNA in an enveloped capsid core. The genome encodes a polyprotein 
which is cleaved by host and viral proteases to produce 11-12 proteins. The locations 
of structural and non-structural proteins are indicated. In ncp viruses, the NS2-3 
protein is further processed to an NS2 and NS3 protein (H. Granzow, Friedrich-
Loeffler-Institut, Insel Riems, Germany, with permission. © 2010) 
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Insertion of host cellular sequences, genome deletion, duplication and other 
rearrangements are commonly observed in cp viruses (Baroth et al., 2000, Becher et 
al., 1999, Becher et al., 1998, Meyers et al., 1998, Qi et al., 1998). Cp strains are 
reported to have an in-frame insertion of ubiquitin and ubiquitin-like genes (UBL) 
(Randow and Lehner, 2009) upstream of the viral NS3 gene providing a cleavage site 
allowing for the release of NS3 by the NS2 autoprotease (Becher et al., 2002). J-
domain protein interacting with viral protein, jiv, a cellular chaperone protein, has 
been shown to interact with and activate autoprotease activity in NS2 (Lackner et al., 
2006). The cytopathic effect of BVDV has been associated with the induction of 
apoptosis by the protease activity of secreted NS3 (Gamlen et al., 2010). A single 
point mutation in NS4B (Y2441C) has also been implicated in changing the virus 
from cp to ncp, suggesting that NS4B may play a role in BVDV pathogenesis (Qu et 
al., 2001). 
The binding and entry of BVDV into cells involves the interaction of viral 
glycoproteins with cell surface receptors. BVDV E2 binds to the complement 
regulatory protein CD46 (Maurer et al., 2004), whilst it is believed that E
rns
 interacts 
with heparin sulphate (Iqbal and McCauley, 2002), after which, entry has been 
shown to be mediated by receptor-mediated, clathrin-dependent endocytosis in a pH 
dependent manner (Lecot et al., 2005, Krey et al., 2005). The viral membrane then 
fuses with the endocytic vesicle membrane resulting in the release of the viral 
genome into the cytoplasm. Replication then takes place at the surface of the 
endoplasmic reticulum (ER), where the positive sense genome is translated into the 
polyprotein, while a negative sense complimentary ssRNA is synthesized and serves 
as a template for new genomic material. Virus assembly occurs at the ER, from 
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which the virion is transported to the Golgi apparatus and buds from the cell 
membrane. E2 is a major determinant of both cell and host tropism (Liang et al., 
2003), and through interaction with the ubiquitous CD46 which is present on all 
nucleated cells, BVDV appears to infect most bovine cells. E2 binding has been 
mapped to two domains on the complement control protein 1 (CCP1) of CD46 (Krey 
et al., 2006) and genetic variation in these regions has been shown to affect 
permissivity and host tropism to BVDV (Zezafoun et al., 2011). The host range for 
BVDV includes most even-toed ungulates (order Artiodactyla), and although many 
species of animals such as goats, sheep, pigs, deer, reindeer, bison llamas and alpacas 
are susceptible to infection with BVDV, domestic cattle are the primary hosts (Ames, 
2008). 
 
1.2 BOVINE VIRAL DIARRHOEA: DISEASE, EPIDEMIOLOGY AND 
IMPACT 
BVD was first described in North America in the 1940s as a transmissible 
disease of unknown origin affecting cattle (Childs, 1946, Olafson et al., 1946). The 
disease was characterized by leucopoenia, fever, depression, diarrhoea, dehydration, 
anorexia, salivation, nasal discharge, gastrointestinal erosions and tissue 
haemorrhages. The causative agent was isolated from separate cases of mucosal 
disease (MD) and viral diarrhoea (VD) in cattle and was found to be cytopathic and 
noncytopathic BVDV respectively (Lee and Gillespie, 1957, Underdahl et al., 1957). 
A cytopathic virus, Oregon C24V was isolated in 1960 from a case of VD and 
attenuated in cell culture for use as a vaccine against BVD (Gillespie et al., 1960, 
Coggins et al., 1961). 
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BVD clinical presentation is dependent on a number of factors such as virus 
strain, immune, reproductive and age status of the host, as well as the presence of co-
infections (Ridpath, 2010, Baker, 1995). The majority of BVDV isolates are well 
adapted to cattle and cause transient acute infection in healthy animals that is cleared 
within 10-14 days. Transient immunosuppression, thought to be a consequence of 
immune cell death within lymph nodes and gut-associated lymphoid tissue (GALT) 
and reduced numbers of circulating leukocytes, may increase susceptibility to 
secondary infection resulting in respiratory and enteric disease (Bolin, 2002). 
BVDV infection has a major impact on the reproductive success of the host 
(Fray et al., 2000). Infection of bulls, in which virus has been shown to be able to 
persist in the testes, can lead to a poor semen quality, while infection in cows can 
result in poor conception rates and reproductive failure. In pregnant animals, 
depending on the time of infection, BVDV may cause abortions, stillbirths or 
teratogenic effects (congenital defects) (Roeder et al., 1986). Foetal infection with 
ncp virus during the first trimester (40 to 120 days) of pregnancy, prior to the 
development of immunocompetence, can result in the birth of persistently infected 
(PI) calves. Only ncp BVDV are able to establish persistent infections. PI calves are 
chronically infected and, in the absence of an adaptive immune response, 
continuously shed virus. Superinfection of PI animals with a related cp virus or by 
mutation of the persistent ncp virus into a cp virus may result in MD, a fatal 
condition characterised by severe lesions of the oral and intestinal mucosa (Ramsey 
and Chivers, 1957, Brownlie et al., 1984). While there has been no direct association 
between virus biotype and severity of disease in vivo, with both cp and ncp viruses 
exhibiting a spectrum of virulence, ncp viruses, which make up the majority of 
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viruses in the field, are more commonly associated with high virulence (Ridpath, 
2005). 
Like BVDV-1, the majority of BVDV-2 infections are asymptomatic. 
However, BVDV-2 infection associated with severe thrombocytopenia and 
haemorrhagic syndrome in cattle was observed in North America in the late 1980s 
(Rebhun et al., 1989) and subsequently in Europe in the early 1990s (Thiel, 1993). 
BVDV-1 viruses makes up more than 90% of isolates in Europe (Vilcek et al., 2005), 
with BVDV-2 being more prevalent in North America (50%) (Ridpath, 2005). 
Despite BVDV being recognized as a global problem, there is only sparse 
information on the prevalence and genotypes of BVDV outside Europe and America. 
Recent studies have attempted to characterize the disease in Africa (Kabongo and 
Van Vuuren, 2004, Handel et al., 2011), Asia (Kampa et al., 2004), South America 
(Stahl et al., 2002) and Australasia (Heuer et al., 2007, Ridpath et al., 2010). Atypical 
bovine pestiviruses which had previously been detected in commercial foetal calf 
serum batches (Peletto et al., 2010, Schirrmeier et al., 2004, Stalder et al., 2005, Xia 
et al., 2011), have also been reported in natural field infections (Ståhl et al., 2007). 
These viruses have been detected in aborted bovine foetuses in Brazil (Cortez et al., 
2006) and in association with cases of abortion and respiratory disease in Italy 
(Decaro et al., 2011b, Decaro et al., 2011a) suggesting that they may have similar 
clinical implications as classical BVDV species.  
BVD has a complex epidemiology, central to which is the role played by PI 
calves that constantly disseminate virus in herds. BVDV transmission in herds is 
either horizontal by contact with PI or acutely infected animals and infection by virus 
in aerosol through the oropharynx and respiratory tracts, or vertically in pregnant 
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animals to the foetus. It is estimated that between 1-2% of cattle worldwide are 
persistently infected with BVDV, with about 50% of herds having PI animals and 
60-80% of cattle becoming exposed in their lifetime (Houe, 1999). BVDV infection 
causes significant economic losses to the cattle industry (Houe, 2003). Economic 
costs of BVDV in Europe have been estimated at between €10 to 40 per calving 
(Houe, 2003) while recent estimates in the United States have put average economic 
costs at approximately $88 per animal (Hessman et al., 2009). Losses are associated 
with reproductive failure, the birth of PI animal, co-infections or highly virulent 
strains resulting in severe disease and death, reduced feed conversion efficiency for 
meat and milk production and costs associated with BVDV control. 
 
1.3 CONTROL AND ERADICATION EFFORTS 
As a result of its economic impact, significant efforts are made to prevent and 
control BVD. BVD control programmes have been classified as either systematic, 
involving a monitored, goal-oriented reduction in incidence and prevalence, or non-
systematic where measures are implemented on a herd to herd basis without 
systematic global monitoring (Lindberg and Houe, 2005). Three key elements for the 
systematic control of BVDV have been described: increased biosecurity to prevent 
the introduction of the infection in BVDV-free herds, the identification and 
elimination of PI animals and increased surveillance to monitor the progress of 
intervention and detect new infections (Lindberg et al., 2006).  
Successful BVD eradication programmes have been implemented in 
Scandinavia (Hult and Lindberg, 2005, Valle et al., 2005) and Austria (Rossmanith et 
al., 2010), while Switzerland is in advanced stages.(Presi et al., 2011). Eradication 
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efforts are also underway in Finland (Rikula et al., 2005), Scotland (Logue, 2010) 
and Germany (Moennig et al., 2005), while the Republic of Ireland has recently 
initiated a voluntary eradication scheme which is planned to be mandatory in 2013 
(Barrett et al., 2011). A pilot eradication scheme has also been launched in England 
(Booth and Brownlie, 2012). 
While virus isolation (VI) is considered the gold standard for virus detection 
in samples, antigen detection by immunohistochemistry (IHC), antigen capture 
ELISA (ACE) and nucleic acid detection by reverse transcriptase-polymerase chain 
reaction (RT-PCR) are more broadly applied (Saliki and Dubovi, 2004, Sandvik, 
2005). VI is the only way of detecting viable virus; although these alternative tests 
have proven robust, reproducible and have good correlation with VI. These tests are, 
however, dependent on monoclonal antibody (mAb) binding to antigen or detection 
of viral RNA that is likely to vary between different diverse virus genotypes. In 
addition to the selection of conserved targets to prevent detection failure, these tests 
are regularly adapted to ensure detection of novel viruses as well as distinguish 
different pestivirus species (Decaro et al., 2012). Detection of BVDV specific 
antibody in milk or blood samples by ELISA or by virus neutralisation test (VNT) in 
exposed or vaccinated animals are also useful for diagnosis. Antibody and antigen 
tests, when used together, help distinguish acute from persistently infected animals in 
which the virus persists in the absence of immune responses. 
Vaccination against BVDV is viewed as an additional biosecurity measure 
aimed primarily at the protection of postnatal calves against disease after maternal 
antibody wanes and of heifers to prevent foetal infections which may result in 
reproductive failure, foetal losses and birth of PI calves (Fulton et al., 2003a). 
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Adoption of BVDV vaccination in Europe is voluntary with usage from 20% to 75% 
(Moennig and Brownlie, 2006). BVDV eradication without vaccination has been 
successfully carried out by large-scale eradication schemes in Scandinavian countries 
where 90-99% of herds are considered free of BVDV (Bitsch and Ronsholt, 1995). 
These schemes are however expensive and intensive and take a long time to 
implement. Vaccination remains the most cost-effective measure of disease control 
in animal health (van Oirschot et al., 1999). Furthermore, in regions with high cattle 
densities and BVDV prevalence, and therefore an increased probability of virus 
reintroduction into fully susceptible BVDV free herds, vaccination can be 
incorporated into systematic control strategies as is the case in Germany (Moennig et 
al., 2005). 
 
1.4 BVDV VACCINES 
According to an online database of livestock veterinary vaccines, 
(www.vetvac.org), there are around 135 registered BVDV vaccine products currently 
in use around the world, mostly in North and South America. These are conventional 
modified live virus (MLV) or inactivated/killed virus vaccines, formulated as either 
monovalent BVDV preparations or multivalent vaccines including other pathogens 
implicated in the bovine respiratory disease complex (BRDC) such as members of 
the Pasteurellaceae family (including Mannheimia haemolytica, Pasturella 
multicoda and Haemophilus somnus), bovine herpesvirus (BHV), parainﬂuenza type 
3 virus (PI3V) and bovine respiratory syncytial virus (BRSV) (Allen et al., 1992). 
Whilst good cross protection is observed against BVDV-1 subgenotypes, the failure 
of BVDV-1 based vaccines to protect against some emerging BVDV-2 viruses, in 
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spite of a degree of antigenic cross-reactivity, has resulted in inclusion of the latter in 
new vaccine preparations (Ridpath, 2005). The need to adapt vaccines to prevalent 
BVDV viruses has also been considered in the development of new vaccines (Fulton, 
2008). 
MLV vaccines are generally thought to be more efficacious since they induce 
high titres of virus neutralising antibodies and provide a longer duration of protection 
from clinical disease than inactivated vaccines that often require booster 
immunizations to achieve improved protection. However, there is a risk that MLVs 
can revert to a virulent form or recombine with field viruses and cause disease and 
vaccinated animals have been reported to develop transient viraemia and shed 
vaccine virus (Fulton et al., 2003b, Grooms et al., 1998). In pregnant animals, live 
vaccines pose the risk of vertical transmission of vaccine virus that can result in 
foetal complications or persistent infection (Ficken et al., 2006). A number of MLV 
vaccines have however been shown to confer foetal protection after BVDV-1 and, in 
a few instances, BVDV-2 challenge (Xue et al., 2009, Fairbanks et al., 2004, Kovacs 
et al., 2003). Live vaccination has also been implicated in post-vaccination mucosal 
disease (pvMD) (Becher et al., 2001). As a result of these safety concerns, live 
vaccines are not licensed in a number of countries such as the United Kingdom, 
Ireland, The Netherlands and Slovenia. 
Whilst inactivated vaccines are thought to be much safer and are therefore 
preferred for vaccination of breeding cattle, bovine neonatal pancytopenia (BNP), a 
syndrome affecting newborn calves characterised by pancytopenia, severe bleeding 
and high lethality, has recently been described in Europe and associated with 
alloreactive antibodies against bovine MHC class I linked to the use of a particular 
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inactivated BVDV vaccine (Bastian et al., 2011, Foucras et al., 2011). This 
highlights a safety concern with regards to the use of crude inactivated virus 
preparations that contain residual host cell derived material. Neither MLV nor 
inactivated vaccines allow for differentiation between infected versus vaccinated 
animals (DIVA) (van Oirschot, 1999), which makes them less suitable for use in 
BVDV eradication efforts. Inactivated vaccines were previously thought to allow 
DIVA because of a lack of production of non-structural proteins such as NS3 and 
hence diminished responses to these targets (Makoschey et al., 2007). This has 
however proved not be the case in a number of studies (Alvarez et al., 2011, Raue et 
al., 2010), due to the presence of non-structural proteins in the crude virus 
preparation prior to inactivation. 
Recent BVDV vaccine developments aim at addressing the shortcomings of 
existing vaccines. An ideal vaccine should: prevent disease, vertical and horizontal 
virus transmission, be safe in pregnant animals, unable to revert to virulence (in the 
case of a live virus vaccine), have broad efficacy to account for virus diversity and 
permit DIVA (Fulton, 2008). Various approaches towards the development of the 
next generation of BVDV vaccines have been evaluated in cattle such as DNA 
vaccination (Nobiron et al., 2003, Young et al., 2005, Liang et al., 2005, Harpin et 
al., 1999), the use of baculovirus or mammalian cell expressed subunit proteins 
(Thomas et al., 2009, Bolin and Ridpath, 1996, Chimeno Zoth et al., 2007), or 
combined as a DNA prime-protein boost regime (Liang et al., 2008, Liang et al., 
2006), all with mixed but encouraging results. Others, such as replication defective 
viral vectored replicons (Elahi et al., 1999b, Mehdy Elahi et al., 1999, Toth et al., 
1999, Baxi et al., 2000, Elahi et al., 1999a), synthetic attenuated infectious cDNA 
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clones (Meyer et al., 2002, Meyers et al., 1996), RNA vaccination (Vassilev et al., 
2001), as well as chimeric pestivirus marker vaccination (Luo et al., 2012) that allow 
DIVA are being assessed for use in vaccines against BVDV and other pestiviruses 
(Tautz and Meyers, 2011). Recent and on-going BVDV vaccine development efforts 
have been the subject of recent reviews (Fulton, 2008, Chase et al., 2004). 
Development of safer, efficacious vaccines will require a better understanding of 
immune responses to BVDV.  
 
1.5 IMMUNOLOGY OF BVDV 
 
1.5.1 BVDV and Innate Immunity 
BVDV has a variety of effects on both innate and adaptive immune responses 
as summarized in Figure 1.2 (Chase et al., 2004). BVDV has been shown to infect 
myeloid cells of the innate immune system and affect their function. The 
microbicidal, chemotactic and antibody-dependent cell-mediated cytotoxic (ADCC) 
functions of neutrophils are impaired (Potgieter, 1995). BVDV infects monocytes, 
producing progeny virus, and in the case of cp BVDV, inducing apoptosis in infected 
monocytes as well as uninfected ‘bystander’ monocytes and lymphocytes via soluble 
factors derived from infected cells (Glew et al., 2003, Lambot et al., 1998). Infection 
with both biotypes of BVDV has been shown to affect alveolar macrophages by 
decreasing phagocytosis, Fc and complement receptor expression, microbicidal 
activity and chemotactic factor production (Peterhans et al., 2003). Infection of 
macrophages with cp or ncp BVDV has also been shown to decrease LPS-induced 
tumour necrosis factor alpha (TNF-α) and superoxide anion production while ncp 
BVDV induces enhanced nitric oxide (NO) synthesis, which may contribute to the 
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immunosuppressive effects associated with BVDV infection (Adler et al., 1997, 
Adler et al., 1996). Other immunosuppressive effects have also been described such 
prostaglandin E2 production (Van Reeth and Adair, 1997), the release of IL-1 
inhibitors (Jensen and Schultz, 1991) and depression of cytokine induced chemotaxis 
(Ketelsen et al., 1979). Additionally, BVDV has been shown to down-regulate MHC 
class II expression in monocytes and macrophages but no effect was observed in 
antigen presentation ability of dendritic cells (Glew and Howard, 2001).  
Cp BVDV induces interferon-alpha (IFN-α) production while ncp virus has 
been shown to inhibit double-stranded RNA (poly(I:C)) induced apoptosis and type I 
IFN (α, β) synthesis in vitro (Peterhans et al., 2003). Ncp virus has also been shown 
to fail to induce type I IFN in persistently infected (PI) foetuses following 
experimental infection of pregnant cows with ncp virus (Smirnova et al., 2008, 
Charleston et al., 2001). Type I IFN plays a role in the elimination of virally infected 
cells through apoptosis and it has been proposed that this response may be 
responsible for preventing foetal infection by cp viruses, whereas ncp BVDV, which 
can inhibit this response in vitro, is able to establish persistent infections. 
Interestingly, while blocking type I IFN to itself, BVDV does not appear to disrupt 
these responses to other unrelated viruses (Schweizer et al., 2006). However, both cp 
and ncp viruses have also been shown to induce type I IFN production in vivo 
(Charleston et al., 2002) and from lineage negative (LIN
-
) CD4
+
 plasmacytoid 
dendritic cells (pDCs) which are present at low frequency in peripheral blood 
(Gibson et al., 2011, Brackenbury et al., 2005). Furthermore, a mutant virus with a 
codon deletion affecting the RNase activity of E
rns
 and deletion of part of the N-
terminal protease, N
pro
, both of which have been shown to inhibit type I IFN, has 
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been shown to prevent the establishment of persistent foetal infection (Meyers et al., 
2007). N
pro
 and E
rns
 have been described to suppress host immune responses by 
blocking the activity of interferon regulatory factor 3 (IRF3) and preventing type I 
IFN production, and by preventing IFN-β production by binding and degrading 
double-stranded RNA, respectively (Hilton et al., 2006, Iqbal et al., 2004). 
Another feature in the establishment of PI is the evasion of adaptive immune 
responses because of the presence of viral antigen during selection of T lymphocytes 
that subsequently recognize the virus as self (Hansen et al., 2010). Interestingly, 
superinfection of PI animals with an antigenically homologous virus may result in 
fatal MD, suggesting that the immune system in these animals is able to recognize 
and mount an active unregulated response against a related virus from the PI virus 
(Collen et al., 2000). The role of natural killer (NK) cells in BVDV immunity has not 
been reported but NS5A has been reported to impair NK responses following 
infection with the related hepatitis C virus (HCV) in humans (Sene et al., 2010). 
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1.5.2 BVDV and Adaptive Immunity 
 
1.5.2.1 Antibody Responses 
The effect of BVDV on circulating B cells varies by study; from an observed 
decrease (Ellis et al., 1988), to showing no effect  (Archambault et al., 2000), to a 
transient increase (Brodersen and Kelling, 1999). Antibody responses to BVDV are 
detectable 2-3 weeks after infection and may plateau after 10-12 weeks (Howard, 
1990). Serum antibodies may be acquired following an active immune response due 
to infection or from maternal colostrum. E
rns
, E1 and E2 glycoproteins induce 
neutralizing antibodies, with E2 being immunodominant and antibodies to structural 
proteins NS2-3 or NS3 have also been detected (Bolin, 1993, Mignon et al., 1992). 
Whilst neutralizing antibodies have been shown to offset disease following 
homologous viral challenge, this does not necessarily result in viral clearance 
(Nobiron et al., 2003). Ncp BVDV infection is associated with higher levels of 
neutralising antibody which develop more quickly than cp BVDV, which showed 
evidence of a stronger cell mediated response and suggesting predominantly Th2 and 
Th1 regulated mechanisms respectively (Lambot et al., 1997).
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Figure 1.2. Interaction of BVDV with innate and adaptive immunity. BVDV has 
various effects on both innate and adaptive immunity with some functions, 
depending on biotype, decreased (in red) or increased (in green). (Institute of 
Veterinary Virology, University of Bern, Bern, Switzerland © 2006 based on Chase 
et al. (2004). Used with permission. 
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1.5.2.2 T cell responses 
The effect of BVDV infection on circulating T cells varies from mild (10-20%) 
to severe (50-60%) lymphopenia depending on strain virulence (Brodersen and 
Kelling, 1999). CD8
+
 cytotoxic T-lymphocytes (CTL) exhibit the greatest decrease 
in numbers followed by CD4
+ helper T cells but there is seemingly little effect on γδ 
T cells (Chase et al., 2004). T cell responses to BVDV have been demonstrated 
following acute infection, as well as after vaccination with killed, MLV and subunit 
E2 vaccines (Beer et al., 1997, Collen et al., 2000, Liang et al., 2005, Rhodes et al., 
1999). Monoclonal antibody mediated cell depletion studies have shown that CD4 T 
cell depletion increased the duration of virus shedding, while CD8 and γδ T cell 
depletion had little effect, suggesting the importance of CD4 T helper cells in 
mediating immunity to BVDV (Howard, 1990). The possible role of depletion of 
other CD4
+
 population such as pDCs was however not addressed. 
Characterisation of T cell responses to BVDV has shown that both CD4 and 
CD8 T cell responses are evoked, with the former producing IL-4 and the latter IFN-
γ, suggestive that the major role for CD4 T cells is to mediate help for the induction 
of B cell antibody responses (Rhodes et al., 1999). However, MHC restricted CTL 
specific for BVDV infected targets have also been reported although their phenotype 
was not discerned (Beer et al., 1997). Assessment of the specificity of the T cell 
response has been limited and focused on CD4 T cells. A preliminary study revealed 
that of a number of viral proteins analysed, C, E
rns
, E2 and NS2-3, were all 
recognised by T cells (Collen and Morrison, 2000). An extension of this study 
mapped an antigenic region on the NS3 protein and showed that amino acid 
substitutions in this area altered T cell recognition (Collen et al., 2000).  
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1.6 AIMS AND OBJECTIVES 
Whilst published data provides good evidence for the role of neutralising 
antibody responses in immunity against BVD, the assessment of T cell responses to 
the various BVDV proteins has been limited. Most studies have assessed T cell 
responses in the context of the whole virus conducted outside the context of the 
identification and selection of vaccine candidate antigens. This study aimed to 
rationally address the development of effective BVDV vaccines by generating and 
using information on T cell responses, which may play a role in the development of 
protection. We hypothesised that T cell responses to certain key BVDV antigens play 
a critical role in immunity to BVD and their inclusion in a subunit vaccine 
formulation will enhance  protection against BVDV challenge. The project therefore 
focused on the characterisation of T cell responses following experimental infection 
with BVD viruses, including the identification of viral proteins that are the targets of 
T cell responses. The project then evaluated a novel vaccine formulation of BVDV 
antigens for its ability to stimulate T cell responses and protect calves against 
challenge infection.  
The specific objectives were: 
1. Characterisation of T cell responses to BVDV proteins following 
experimental infection of calves with cytopathic BVDV-1a virus. (Chapter 3) 
2. Comparative analysis of immune responses following experimental infection 
of calves with BVDV-1a and an Asiatic atypical bovine pestivirus (Chapter 
4) 
3. Evaluation of the immunogenicity and efficacy of biodegradable nanoparticle 
vectored viral proteins as a vaccine against BVDV-1 (Chapter 5) 
2 MATERIALS AND METHODS 
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2.1  Bovine Viral Diarrhoea Viruses 
Cytopathic BVDV-1a Oregon C24V (Coggins et al., 1961) was propagated in 
vitro by inoculation of sub-confluent foetal bovine turbinate (BT) cell monolayers. 
BT cells were maintained in Minimum Essential Medium (MEM) with 7.5% sodium 
carbonate, 5% lactalbumen hydrosate, 1mM sodium pyruvate, 2mM glutamine, 100 
U/ml penicillin, 100 μg/ml streptomycin and 20μg/ml nystatin (all Invitrogen, Life 
Technologies, Paisley, UK) and 10% BVDV-free foetal bovine serum (FBS; 
Autogen Bioclear, Calne, UK) (BT medium). After 4 days, the supernatant was 
collected and pooled with a freeze-thawed cell lysate. The resultant pool was 
clarified by centrifugation at 524 x g for 10 minutes, aliquoted and stored at -80°C. 
Virus titres were determined as the median (50%) tissue culture infectious dose 
(TCID50) using the Spearman-Kärber method (Finney, 1978) following 
immunoperoxidase staining (Meyling, 1984). Mock virus supernatant was prepared 
in an identical manner from uninfected BT cells.  BVDV-1 Oregon C24V was select 
as it is a prototype BVDV-1 strain which has been attenuated for vaccination 
purposes and for which full genome sequence data  was available for synthesis of a 
proteome-wide peptide library. Two noncytopathic BVDV isolates were used in the 
second study: BVDV-1a strain Horton-916 (Ho916), isolated from a clinically severe 
fatal outbreak of BVD in the United Kingdom (Hibberd et al., 1993) and an atypical 
bovine pestivirus strain, Th/04_KhonKaen (TKK) which was recovered from a dairy 
calf in Thailand (Liu et al., 2009a). BVDV-1 Horton-916 was selected as a strain 
known to cause disease in cattle in the UK and TKK virus was included as a 
genetically distant atypical bovine pestivirus.  BVDV-1 Horton-916 was also used as 
the challenge virus in the final vaccination study. All experimental calves received an 
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intranasal (i.n.) inoculation on 41 dpv with 5x10
6
 TCID50 in 2ml, which was 
confirmed by back titration. The virus dose was selected as it had been previously 
used at this dose to induce clinical disease in an experimental infection (Dr. Rebecca 
Strong, personal communication). 
 
2.2 Ethical Consideration 
All animal work was approved by the Animal and Plant Health Agency 
Ethics Committee and all procedures were conducted in accordance with the UK 
Animals (Scientific Procedures) Act 1986 under UK Home Office Project Licence 
permit number 70/6836.   
 
2.3 Animals, experimental infection and vaccination 
Six 3-4 month old Holstein-Friesian calves were recruited; four were 
inoculated intransally (i.n.) with a ‘low’ dose (104 TCID50) of BVDV Oregon C24V 
(2 ml divided equally between each nostril and administered using a mucosal 
atomization device MAD-300, Wolfe Tory Medical, USA) and then similarly 
inoculated with a ‘high’ dose (107 TCID50) after a period of four weeks. BVDV 
Oregon C24V was selected as a reference cytopathic BVDV-1a strain attenuated for 
vaccine use. The ‘low’ dose was expected to prime immune responses and the the 
higher dose to boost them. Two calves received two doses of control mock virus 
supernatant and were housed separately. Animals were monitored for clinical signs 
of infection and blood samples longitudinally collected to assess viraemia, antibody 
and T cell responses.  
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For the second experiment, twenty 3–5 month old, BVDV-free Holstein 
calves were divided into 4 groups of 5 calves each and inoculated with 10
5
 TCID50 in 
10ml (5ml intranasal and 5ml intramuscular) of Ho916, TKK or both viruses 
(Ho916/TKK). Control animals (Controls) were inoculated with 10ml of Eagle’s 
Minimal Essential Medium (E-MEM) (Invitrogen). The viruses used represented a 
typical field virus, Ho916, and newly described genetically divergent atypical 
pestivirus, TKK, for comparative purposes. The doses used were considered 
adequate to induce clinical disease. Assessment of clinical scores including rectal 
temperature and sampling of blood and nasal secretions was conducted up to 45 days 
post-infection (45 dpi). The details of the procedures and outcome of the 
experimental infection are described by Larska et al. (2012) (Appendix A). 
For the final experiment, eighteen 6-8 month old male Holstein-Friesian 
calves were used. Published data from an experimental E2 subunit vaccine study 
(Thomas et al., 2009) was used to calculate a sample size sufficient to measure 
differences in immune responses between vaccinated and control animals with 
significant statistical power. A group size of six was found to enable measurement of 
virus neutralising antibody responses with a power of 0.93 based on mean variances 
(range of 0.68-1, based upon maximum and minimum variances) and total virus-
specific antibody response with a power of 0.81 (range, 0.54-1). The animals were 
tested for the absence of BVDV antibody and antigen and randomly assigned into 
three experimental groups prior to vaccination.  
 
2.4 Vaccine preparations and immunization 
A formulation of PLGA nanoparticles encapsulating Escherichia coli 
expressed helicase domain of BVDV-1 CP7 NS3 protein (a kind gift from Prof. Till 
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Rümenapf, Institute of Virology, Giessen, Germany) and poly(I:C) (Sigma-Aldrich, 
Poole, UK) and coated with BVDV-1 NCP7 and NADL baculovirus derived E2 
protein ectodomain (a kind gift from Dr. Thomas Krey, Pasteur Institute, Paris, 
France) (Vaccine NP; approximately 150g NS3, 50g E2 and 80μg poly(I:C) per 
dose) was prepared and quality controlled at the APHA (Walters et al., unpublished 
data). PLGA nanoparticles similarly formulated with poly(I:C) and ovalbumin 
protein (Sigma-Aldrich) were used as a negative control (Control NP). The quantity 
of antigen and TLR ligand coating or encapsulated in the nanoparticles was 
determined empirically during formulation and dosage was determined by quantities 
that were considered adequate in published literature. (Bruschke et al., 1997, Thomas 
et al., 2009). A licensed inactivated vaccine (IAV), Bovidec® (Novartis Animal 
Health, Camberley, United Kingdom), was used as a reference standard for both 
immunogenicity and efficacy. According to the manufacturer’s specifications, 
Bovidec consists of an inactivated BVDV-1a strain, KY1203nc (Clarke et al., 1987) 
in Minimum Essential Medium (5 x 10
6
 TCID50 per 4ml dose), which is adjuvanted 
with Quil A (1 mg per dose) and stabilised with thiomersal. Calves (six per group) 
received a primary subcutaneous (s.c.) inoculation of Vaccine NP or Control NP in 
2ml or IAV in 4ml. A similar booster inoculation was given at 21 days post-
vaccination (dpv). 
 
2.5 Clinical and haematological monitoring 
Clinical scores and rectal temperatures were monitored prior to viral 
challenge and on a daily basis subsequently. For clinical scoring, seven parameters 
were assessed: depression, ocular discharge, nasal discharge, dyspnoea, cough, 
inappetance and diarrhoea. These were individually scored as normal (0), slightly 
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altered (1), a distinct clinical sign (2) or a severe symptom (3). Weights were also 
monitored weekly prior to and after viral challenge. 
Platelet and leukocytes were enumerated by volumetric flow cytometry prior 
to viral challenge and every 2-3 days thereafter. Briefly, for platelets, 500μl EDTA 
blood was centrifuged at 200g for one minute in a microcentrifuge and 5μl of 
platelet-rich plasma was transferred into a FACS tube containing 2ml of CellFix 
solution (BD Biosciences, Oxford, UK), mixed and incubated for 10 minutes at room 
temperature (RT). 25μl was then acquired on a volumetric flow cytometer 
(MACSQuant Analyzer; Miltenyi Biotec, Bisley, UK) and counts obtained by gating 
on platelets based on their forward and side scatter characteristics on logarithmic 
scales. Platelet gating was validated by staining with mouse anti-bovine CD61 
(platelet glycoprotein IIIa, AbD Serotec, Oxford, UK). For total leukocyte counts, 
50μl EDTA blood was stained with 5μl of anti-ovine CD45-FITC mAb (AbD 
Serotec) diluted 1 in 5 in PBS with 1% FBS and 0.1% sodium azide (FACS buffer) 
and incubated for 15 minutes at RT in the dark. 0.945ml of FACS Lysing solution 
(BD Biosciences) was added for 10 minutes at RT to lyse erythrocytes and fix 
leukocytes. 25μl was acquired and cell counts were obtained by gating FITC positive 
events. Granulocytes (eosinophils and neutrophils), monocytes and lymphocytes 
were distinguished by plotting intracellular complexity (side scatter) against CD45 
expression (Pelan-Mattocks et al., 2001). Both platelet and leukocyte counts per ml 
were obtained by multiplying the count by dilution factor and acquired volume 
conversion to 1ml. 
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2.6 Assessment of viraemia 
 
2.6.1.1 Detection of viral antigen 
The BVDV envelope RNase glycoprotein, E
rns
, was detected in heparinised 
blood samples using the HerdChek® BVDV Antigen/Serum Plus ELISA kit 
according to the manufacturer’s instructions (IDEXX Switzerland AG, Liebefeld-
Bern, Switzerland). Briefly, 50μl of sample, including positive and negative controls, 
were added to microtitre plate wells coated with immobilized anti-BVDV E
rns
 mAb 
and incubated for two hours at 37°C. The captured antigen was then detected using a 
secondary E
rns
 specific mAb and horseradish peroxidase (HRP) conjugate. Unbound 
conjugate was then washed off and a chromogenic substrate solution was added. The 
reaction was stopped by the addition of 100μl of sulphuric acid to each well and 
absorbance at 450nm measured on a spectrophotometer. The presence of BVDV 
antigen was determined as corrected optical density (COD) by subtracting the mean 
negative OD from the mean sample OD. COD values which were greater than 0.3 
were considered to be positive. 
 
2.6.1.2 Viral nucleic acid detection 
BVDV RNA was extracted from EDTA blood samples using the QIAamp 
Viral RNA extraction kit (Qiagen, Crawley, UK) as described by the manufacturer. 
The RNA quality (OD260/OD280 ratio) and quantity (OD260) was assessed on a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA) and the material stored at −80°C. BVDV RNA extracted from EDTA blood 
was detected using a single tube nested quantitative RT-PCR (qRT-PCR) TaqMan® 
assay (McGoldrick et al., 1999).  cDNA synthesis from RNA was first performed by 
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reverse transcription using the V326 (5’ TCA ACT CCA TGT GCC ATG TAC 3’) 
primer (Vilcek et al., 1994). First round PCR (10 cycles) using the pestivirus primers 
V326 and V324 (5’ ATG CCC W(A/T)TA GTA GGA CTA GCA 3’) produced a 
300bp amplicon, after which a second round nested PCR (40 cycles) was used to 
copy the first round amplicon using primers A11 (5’ AGT ACA GGG TAG TCG 
TCA GTG GTT CG 3’) and A14 (5’ CAA CTC CAT GTG CCA TGT ACA GCA G 
3’) to produce a 220bp amplicon (Belak and Ballagi-Pordany, 1993). A pan-
pestivirus TaqMan® probe (FAM 5’ CTG ATA GGG TGC TGC AGA GGC CCA 
CT 3’ TAMRA) was detected during the extension phase in each PCR cycle on a 
Stratagene MX3000P Real-Time PCR machine (Agilent Technologies, La Jolla, CA, 
USA) and data analysed on the MX Pro 4.1.0c Software (Agilent Technologies). 
Relative quantities of viral RNA in samples were quantified by interpolation against 
a 10 fold dilution of RNA extracted from an equivalent volume of virus (BVDV-1a 
Oregon C24V) of known titre (standard range from 10
7.55 
to 10
0.55
 TCID50/ml) (La 
Rocca and Sandvik, 2009). 
 
2.7 BVDV sequence analysis 
E2 and NS3 coding sequences from Ho916 were provided by Dr. Rebecca 
Strong (APHA, Addlestone, United Kingdom). Predicted amino acid sequences were 
aligned against E2 and NS3 sequences from the published genome of reference strain 
BVDV-1 Oregon C24V (C24V) (AF091605.1) (Coggins et al., 1961) and 
Th/04_KhonKaen (FJ040215.1) using the clustalw algorithm on MegAlign 
(DNAStar Lasergene 9 Core Suite, Madison, WI, USA).  Sequence distances were 
calculated as divergence based on comparison of sequence pairs in relation to a 
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phylogeny reconstruction by MegAlign and as percent identity, which compares both 
sequences directly without accounting for phylogenetic relationships. 
 
 
 
2.8 Detection of virus and antigen specific antibody responses 
 
2.8.1 BVDV specific antibody 
Total BVDV-specific antibody was detected in serum samples using a 
commercial indirect ELISA (HerdChek® BVDV Antibody ELISA, IDEXX 
Laboratories, Wetherby, UK). In brief, 25μl of serum samples, negative and positive 
controls were each diluted to 100μl and added to a 96 well plate coated with 
immobilized BVDV antigen, mixed thoroughly and incubated for 90 minutes at room 
temperature. After, the wells were washed five times and 100μl of anti-bovine HRP 
conjugate added to each well and incubated for a further 30 minutes at RT. 
Following another wash step and 10 minutes incubation with 100μl per well of 3, 3’, 
5, 5’-tetramethylbenzidine (TMB) substrate at RT in the dark, 100μl of stop solution 
was added and absorbance measured at 450nm. Results were calculated as sample to 
positive control ratios (S/P) using the following formula:  
 
Where, OD – Optical density, S – Sample, NC – Negative control, PC – Positive 
control. Samples with an S/P value greater than or equal to 0.30 were considered 
positive, those less than 0.2, negative, and anything between 0.2 and 0.3 were 
inconclusive.  
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In Experiment two (Chapter four), BVDV specific antibody was detected in 
serum samples using an indirect BVDV antibody ELISA (Svanovir®, Svanova 
Biotech AB, Uppsala, Sweden). In brief, 10μl of samples, negative and positive 
controls in 90μl of diluents were added to a 96 well plate with immobilized BVDV 
or control antigen and incubated for one hour at 37°C. After, the wells were washed 
five times and 100μl of anti-bovine HRP conjugate was added to each well and 
incubated for a further hour at 37°C. Following another wash step and 10 minutes 
incubation with 100μl per well of TMB substrate at RT in the dark, 50μl of stop 
solution was added and absorbance measured at 450nm. Corrected OD values were 
obtained by subtracting the OD values of the control antigen well from the 
corresponding BVDV antigen well. Antibody values were calculated as follows:  
 
Where, PP – percent positive value, cOD – corrected optical density, S – sample, NC 
– negative control, PC – positive control. Samples with a PP value greater than or 
equal to 10 were considered positive in accordance with the kit instructions. 
 
2.8.2 E2 and NS3 specific antibodies  
Commercial blocking ELISA kits were used for the detection of antibodies 
against NS3 (SVANOVIR® BVDV p80, Svanova Biotech, or Pourquier® ELISA 
BVD p80, Institut Pourquier, Montpellier, France) and E2 (VDPro® BVDV, Jeno 
Biotech Inc., Chuncheon, Republic of Korea) according to the manufacturer’s 
instructions. Briefly, 10μl of serum diluted in 90μl of diluent (NS3 ELISA) or 50μl 
serum in 50μl of diluent buffer (E2 ELISA) was plated in duplicate in recombinant 
antigen coated plates and incubated for one hour. A positive and negative control 
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was provided for each assay. The plates were then washed three times in PBS with 
0.05% Tween-20 (PBS-Tween) wash buffer, 100μl of conjugate (anti-NS3 or E2-
horseradish peroxidise) added to each well and incubated for another hour. The 
sample and conjugate incubations for the NS3 ELISA were done at 37°C, while the 
E2 assay incubations were performed at room temperature (RT). After a second wash 
step, 50 or 100μl of TMB substrate was added and incubated for 10-20 minutes at 
RT. Sulphuric acid was used to stop the reaction and the optical density measured at 
450nm. For both assays, the percentage inhibition was calculated for each sample as 
follows: 
 
Where, PI – Percentage inhibition, OD – Optical Density, Nc – Negative Control, S – 
Sample. Samples with a PI value greater than 30% were considered positive.  
 
2.8.3 Serum virus neutralization titres 
 To determine virus neutralising antibody titres (VNT), test sera was heat 
inactivated for 30 minutes at 56°C after which 50μl of a two-fold dilution in BT 
medium from 1:5 to 1:640 was added into duplicate wells of a flat-bottomed 96-well 
microtitre plate (Nunc). Positive and negative control sera were also tested. An equal 
volume containing 100 50% tissue culture infective dose (TCID50) of BVDV-1a 
Oregon C24V was added and incubated for 1 hour at 37°C. A back titration of virus 
was performed to check the potency of the virus (working range 30-421 TCID50). BT 
cells were then added (1.5 x 10
4 in 50μl) and incubated at 37°C for 5 days in a 
humidified 5% CO2 atmosphere. After, the plates were washed in PBS and then fixed 
with 20% acetone (v/v) for 10 minutes, excess acetone removed by tapping on a 
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paper towel and dried under a lamp for 3-4 hours. The plates were then stored at -
20°C for at least 30 minutes after which immunoperoxidase staining for virus was 
conducted as described previously (Meyling, 1984). Serum VNTs were calculated as 
reciprocal of the highest serum dilution that inhibited virus growth by 50% using the 
Spearman–Kärber method and expressed on a log2 scale. 
In Experiment 2 (Chapter 4), VNTs were determined as described previously 
on serum samples from the different inoculation groups at 42 dpi. A two-fold 
dilution series (1:10 to 1:1280) of heat inactivated (56°C for 30 minutes) serum, in 
duplicate with Ho916, TKK, BVDV-1a C24V (Coggins et al., 1961), BVDV-2 
50263 (Wakeley et al., 2004) or Border Disease Virus 1 (BDV-1) S137/4 (Vantsis et 
al., 1976). The extent of cross reactivity (serological relatedness) was calculated as a 
percentage, P, of heterologous virus neutralisation (VN) compared to homologous 
VN values as follows (Ridpath et al., 2010): 
 
Where BA is the VNT of antiserum A against virus B, and AA is the homologous 
VNT against virus A.  
For Experiment 3 (Chapter 5), virus neutralising antibodies titres were 
determined by incubation of two-fold dilution of heat-inactivated serum (1:5 to 
1:81920) with the challenge virus, BVDV-1a Horton 916 (100 TCID50 per well). 
 
2.9 BVDV T cell Responses 
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2.9.1 BVDV Peptide Library 
A library of 972 overlapping 16-mer peptides offset by 4 amino acids 
(Pepscan Presto BV, Lelystad, The Netherlands) representing the BVDV-1a Oregon 
C24V polypeptide sequence (GenBank Accession No. AF091605) were dissolved in 
sterile acetonitrile (Sigma-Aldrich, Poole, UK) to make 5mg/ml stocks and stored at 
-80°C. The peptide stocks were diluted in RPMI-1640 medium (Invitrogen) 
supplemented with 2mM L-glutamine, 20mM HEPES, 100U penicillin and 
100μg/mL streptomycin with 10% sterile FBS (cRPMI) and used at 2μg/ml for each 
peptide. The peptides were pooled to represent different viral proteins with minimum 
overlap between proteins and the longer proteins represented by two pools. Bovine 
peripheral blood mononuclear cells (PBMC) were cultured in the presence of peptide 
pools (1μg/ml final) for 24 hours and then viability assessed by incubating cells for a 
further 10 minutes with a cell viability dye (7AAD, BD Biosciences) and analysed 
on a flow cytometer. 
For Experiment 2 (Chapter 4), overlapping 15-mer peptides offset by 4 amino 
acids (JPT Peptide Technologies GmbH, Berlin, Germany) were synthesised 
covering the E2 protein from Ho916 and TKK, and the NS3 protein of C24V based 
on the divergence of the E2 and conservation of NS3 between the three viruses. 
Lyophilised peptides were dissolved in sterile 0.1M HEPES, pH 7.4-buffered 40% 
acetonitrile and combined to make the respective E2 and NS3 protein pools. The 
peptide stocks were diluted in cRPMI. 
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2.9.2 Isolation and ex vivo stimulation of peripheral blood mononuclear cells 
Heparinised blood was collected from calves on a weekly basis and 
peripheral blood mononuclear cells (PBMC) isolated by density centrifugation. 
Blood was diluted 1:1 in HBSS (Invitrogen) and layered over an equal volume of 
Biocoll Separation Solution (density of 1.077g/ml; Autogen Bioclear) and 
centrifuged at 1000g for 30 minutes at room temperature (RT) with the brakes off. 
PBMC were harvested from the biocoll interface and washed thrice in HBSS by 
centrifugation at RT. PBMC were resuspended in cRPMI. Cell counts were obtained 
by flow cytometry as described above, with events gated on typical linear SSC and 
FSC characteristics for PBMC. The PBMC density was adjusted to 5 x 10
6
 cells/ml 
and 100μl transferred to wells of a 96 well round bottom microtitre plate. In 
Experiment 1 (Chapter 3), cells were stimulated in duplicate wells with 100μl of 
peptide pools representing the individual BVDV proteins at 2μg/ml or BVDV-1a 
Oregon C24V at a multiplicity of infection (MOI) of 5. Live virus was used for the 
ex vivo stimulation to ensure the production and presentation of both structural and 
non-structural BVDV proteins in antigen presenting cells. cRPMI or mock-infected 
BT supernatant and 10μg/ml pokeweed mitogen (PWM; Sigma) were used as 
negative and positive controls respectively. The cells were incubated at 37°C for 24 
or 48 hours for flow cytometry or IFN-γ ELISA analysis respectively. In Experiment 
3 (Chapter 4), cells were stimulated in duplicate wells with 100μl of peptide pools 
representing the E2 and NS3 proteins at 1μg/ml or viruses at a multiplicity of 
infection (MOI) of 1. Medium or mock-infected BT supernatant and PWM were 
again used as negative and positive controls respectively.  The cells were incubated 
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at 37°C for 48 hours after which cell-free supernatants were harvested after 
centrifugation and stored at -80°C until analysis for detection of cytokines.  
 
2.9.3 Detection of bovine IFN-γ and MIG/CXCL9 
Forty-eight hours post-stimulation, PBMC were resuspended and then 
centrifuged at 300g for 2 minutes and the cell-free supernatants collected for 
cytokine detection or stored at -80°C until use. Interferon-gamma (IFN-γ) in culture 
supernatants was measured using a bovine IFN-γ ELISA (Bovigam, Prionics AG, 
Schlieren-Zurich, Switzerland) according to the manufacturer’s instructions or an in-
house ELISA protocol. Briefly, 96 well NUNC MaxiSorp microplates (Thermo 
Fisher Scientific, Loughborough, UK) were coated with 100μl/well of mouse anti-
bovine IFN-γ mAb (CC330, AbD Serotec) at 5μg/ml in 0.05M carbonate/bicarbonate 
coating buffer (pH 9.6) (Sigma) and incubated overnight at RT. The plates were then 
washed with PBS with 0.05% Tween-20 (wash buffer) and incubated for an hour at 
RT with 300μl/well PBS supplemented with 1% bovine serum albumin (BSA) and 
0.05% Tween-20 (blocking buffer). The blocking buffer was aspirated and 50μl of 
test supernatant added to duplicate wells. A two-fold serial dilution of recombinant 
bovine IFN-γ (AbD Serotec) in cRPMI, starting at 50ng/ml, and medium alone was 
added as standard/positive and negative controls respectively. After one-hour 
incubation at RT, the plates were washed five times with wash buffer and 100μl/well 
biotin-conjugated mouse anti-bovine IFN-γ mAb at 5μg/ml (CC302-biotin, AbD 
Serotec) added. The plate was incubated and washed as above and 100μl/well 
streptavidin conjugated horseradish peroxidise (SA-HRP; GE Healthcare, Little 
Chalfont, UK) diluted 1/1000 in blocking buffer and incubated for 45 minutes at RT. 
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After a final wash, 100μl/well of TMB substrate (Sigma) was added and incubated 
for 15 minutes at RT, before stopping the reaction with 100μl/well 1.8N sulphuric 
acid and absorbance at 450nm measured with a background correction (reference 
filter 630nm) within 5 minutes on a FLUOstar Optima Plate Reader (BMG Labtech, 
Aylesbury, UK).  In Experiment 3 (Chapter 5), the in-house IFN-γ ELISA was 
modified to use black opaque 96 well flat-bottom plates (View-plate-96, 
PerkinElmer, Seer Green, USA) and after the final wash, 100ul of Supersignal® 
ELISA Femto Substrate (equal parts luminol/enhancer and stable peroxidise solution; 
Thermo Scientific) was added per well and mixed for one minute using a microplate 
mixer and the relative light units (RLU) measured on a luminometer (≈425nm) 
(Victor™ X4 Multiplate Plate Reader; Perkin Elmer). IFN-γ was measured as it is 
considered the prototype marker of anti-viral type 1 T cell responses (Wheelock, 
1965).  
Levels of bovine monokine induced by gamma (MIG/CXCL9) were assessed 
using a commercial ELISA kit (Bovine CXCL9 (MIG) VetSet™ ELISA 
Development Kit (Kingfisher Biotech Inc., St Paul, MN, USA). Briefly, 100μl of 
sample per well in duplicate was added to CXCL9 antibody coated plate and 
incubated for an hour at RT. A two-fold dilution series of standard from 30 to 
0.469ng/ml was also added. The plates were then washed four times in wash buffer 
after which 100μl of detection antibody was added and incubated for another hour at 
RT. Following a similar wash step, 100μl of Streptavidin-HRP was added and 
incubated for 30 minutes at RT. TMB substrate solution (100μl per well) was added 
after a final wash and incubated in the dark for 30 minutes. The reaction was then 
stopped by adding 100μl of 0.18M sulphuric acid and absorbance measured at 
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450nm on a spectrophotometer (Victor™ X4). MIG/CXCL9 was selected as it has 
been reported to be a monokine induced by IFN-γ and serves as an amplified and 
functional measure of IFN-γ responses (Berthoud et al., 2009).  
 
2.9.4 Multiparametric Flow Cytometry 
To accumulate intracellular cytokine, brefeldin A (GolgiPlug, BD 
Biosciences) was added (0.2μl/well) to PBMC cultures and for the final 4 hours of 
the 24 hour incubation period before performing flow cytometric analysis. PBMC 
were washed twice in PBS by centrifugation at 300g for 2 minutes, resuspended in 
50μl PBS and incubated with 0.2μL/well Near Infra-Red Live/Dead Viability Dye 
(Invitrogen) for 30 minutes at 4°C protected from light. Cells were washed with 
FACS buffer and stained with mouse monoclonal antibodies: CD4-FITC, CD8β-PE 
or CD335-Alexa Flour 488 (all AbD Serotec) and γδ-TCR (GB21A; VMRD, 
Pullman, WA, USA) for 15 minutes at room temperature. Since the γδ-TCR antibody 
was unconjugated, cells were subsequently stained with anti-mouse IgG2a,b-PE 
secondary antibody (BD Biosciences) for an additional 15 minutes at room 
temperature.  The cells were then washed twice with FACS buffer and then fixed and 
permeabilised using CytoFix/CytoPerm Solution (BD Bioscience) for 20 minutes at 
4°C. After two washes in BD Perm/Wash Buffer (BD Biosciences), the cells were 
resuspended in a 50μL volume and stained with mouse anti-bovine IFN-γ antibody or 
an irrelevant isotype control antibody both conjugated to Alexa Flour-647 (AbD 
Serotec), at 4°C for 30 minutes in the dark. The cells were given two final washes in 
BD Perm/Wash buffer and resuspended in FACS buffer prior to flow cytometric 
analysis. Cells were analysed by gating on viable cells (Live/Dead Fixable Dead Cell 
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dye negative) in the lymphocyte population, and defined lymphocyte subpopulations 
were then gated upon and their expression of IFN-γ assessed. 
 
2.9.5 Measurement of cytokines by ELISA and MSD multiplex assay 
 A number of cytokines associated with a cell-mediated response were 
assessed following ex vivo stimulation of PBMC with viruses or peptide pools. IFN-γ 
in culture supernatants was measured using a bovine IFN-γ ELISA as described 
above. Multiple cytokines (Table 2.1) were detected and quantified using a custom-
designed multi-array electrochemiluminescence detection assay (Meso Scale 
Discovery (MSD), Gaithersburg, MD, USA) as described previously (Coad et al., 
2010). Briefly, 96-well multispot microtiter plates bearing a patterned array of 
capture antibodies to the different cytokines on the bottom of the wells were blocked 
with Diluent 7 buffer and shaken for 30 minutes. A master mix of recombinant 
cytokine standards (Table 2.1) was prepared and serially diluted in Diluent 7 buffer. 
Samples and standards (25μl per well) were added to the plate after removal of 
blocking buffer and incubated for 1 hour at RT with shaking. Afterwards the plate 
was washed three times with PBS with 0.05% Tween-20 (wash buffer) and 25μl per 
well detection antibodies conjugated to the ruthenium-based MSD Sulfo-TAG™ 
reagent and streptavidin Sulfo-TAG and incubated for 1 hour at RT while shaking. 
For each plate, 1.8μl streptavidin Sulfo-TAG™ (0.3μg/ml final) and 60μl of each 
antibody (each at 1μg/ml final) was made up to 3000μl of Diluent 8 and 25μl 
dispensed per well. The plates were washed three times and 150μl of MSD read 
buffer (diluted 1:1 with distilled water) added to each well. The Plates were then read 
with an enclosed CCD camera on a Sector Imager 6000 (MSD), datasets analysed on 
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the Discovery Workbench 3.0 Software and the samples quantified against standard 
curves. 
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Table 2.1. Cytokine standards for MSD multiplex assay 
Cytokine Supplier Concentration (Top Standard) 
IFN-γ Piercea 100ng/ml 
IL-1β AbD Serotecb 20ng/ml 
IL-4 Pierce 2ng/ml 
IL-6 IAH
c
 25U/ml 
IL-10 IAH 30U/ml 
IL-12 IAH 500U/ml 
MIP-1β MSD 10ng/ml 
a
Pierce, Thermo Fisher Scientific, Loughborough, United Kingdom, 
b
AbD 
Serotec, Kidlington, United Kingdom, 
c
Institute for Animal Health, 
Compton, United Kingdom 
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2.10 Statistical Analysis 
Graphpad Prism 5.04 (Graphpad software, LaJolla, CA, USA) was used for 
graphical and statistical analysis. Analysis of variance (ANOVA) followed by a 
Bonferroni’s post-test was used for the analysis of the effects of viral challenge or 
vaccination on antibody and cellular immune responses in the different treatment 
groups.  Data was represented as means with standard deviation (SD) or standard 
error of means (SEM) shown to indicate the uncertainty around the estimate of the 
group means.  
 
3 T CELL RESPONSES TO VIRAL PROTEINS FOLLOWING 
EXPERIMENTAL INFECTION OF CALVES WITH CYTOPATHIC 
BOVINE VIRAL DIARRHOEA VIRUS TYPE I 
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SUMMARY 
The characterisation of the target of protective immune responses to BVDV is 
an important prerequisite in the design of next-generation vaccines. This study aimed 
to rationally address the development of more efficacious vaccines by characterising 
the kinetics and specificity of CD4 and CD8 T cell responses of cattle rendered 
immune to BVDV following recovery from infection. Four calves were inoculated 
with a low titre (10
4
 TCID50) of cytopathic BVDV and received a secondary high 
titre (10
7
 TCID50) inoculation 4 weeks later. PBMC were stimulated with live BVDV 
or synthetic peptide pools spanning the entire BVDV proteome and IFN-γ secretion 
assessed by ELISA or by flow cytometry. IFN-γ responses to BVDV peptide pools 
were not detected until 28 days after the second inoculation. The dominant responses 
were observed against peptide pools representing the E2 and NS3 proteins, and these 
responses were still detectable one year after experimental infection. Analyses to 
define the phenotype of these BVDV antigen-specific T cell responders, whilst not 
optimal, showed evidence of CD4
+
 IFN- responses to E2 and NS3. IFN-γ secretion 
in response to ex vivo stimulation with BVDV, as measured by ELISA, was detected 
in all calves including the uninfected control. Flow cytometric analyses revealed that 
natural killer (NK) cells secreted IFN-γ in response to the virus, regardless of the 
animals’ immune status. However, IFN-γ secretion by both CD4 and CD8 αβ T cells 
was significantly greater in the immune calves. This data supports the further 
evaluation of BVDV E2 and NS3 proteins as vaccine candidate T cell antigens. 
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3.1 INTRODUCTION 
Studies of the immune response to bovine viral diarrhoea virus (BVDV) have 
suggested a role for both B and T cell responses in protection (Chase et al., 2004, 
Kapil et al., 2008, Howard, 1990, Potgieter, 1995). The characterisation of antibody 
and T cell targets of protective immune responses to BVDV is an important 
prerequisite in the design of next-generation vaccines.  
There is good evidence for the role of T cell responses in BVDV immunity. 
Calves vaccinated in the presence of maternal antibodies, whilst unable to mount an 
effective antibody response, do generate memory T cells sufficient to protect against 
viral challenge (Endsley et al., 2003). Both CD4 and CD8 T cell responses have been 
shown to be evoked by BVDV (Rhodes et al., 1999), although mAb depletion of 
CD4 T cells but not CD8 or γδ T cells has been shown to increase the duration of 
virus shedding (Howard et al., 1992). These CD4 T cell responses have been shown 
to be directed principally against E2 and NS3 but also to other proteins such as the 
N
pro
, C and E
rns 
proteins (Lambot et al., 1997, Collen and Morrison, 2000, Collen et 
al., 2002). A comparison of responses to all the different BVDV proteins in the 
course of natural or experimental infection has, however, not been conducted.   
 This study aimed at characterising the T cell responses to BVDV and to its 
constituent viral proteins following experimental infection with a BVDV-1a 
reference strain, Oregon C24V. The specific objectives were to characterise the 
kinetics and phenotype of T cell responses to BVDV proteins following experimental 
infection and to define the specificity of the BVDV specific T cell responses. The 
expected definition of T cell responses that are boosted upon re-challenge will serve 
as the populations for which we intend to target through vaccination and will be used 
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as tools to identify the relevant vaccine candidate antigens.  Defining the specificities 
of the T cell responses elicited in our challenge model system will allow the 
identification of proteins or portions of proteins which could be evaluated for their 
vaccine potential. 
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3.2  RESULTS 
3.2.1 Outcome of BVDV Infection 
The experimental animals were assessed for the presence of BVDV antibody 
and antigen. Four of the calves were found retrospectively to be BVDV antigen 
negative but antibody positive prior to experimental infection indicating pre-
exposure to BVDV while two were BVDV naïve (Table 3.1). This was unexpected 
as the animals were sourced as BVDV naïve calves from a reputable supplier. . Upon 
investigation tit was determined that the supplier had erroneously only pre-screened 
the calves for the presence of BVDV antigen and not antibody. The BVDV antigen 
ELISA is used to detect acutely infected and persistently infected (PI) animals, the 
latter of which are of great concern in BVD control, but this is not an appropriate 
assay to assess previous infection with BVDV. BVDV antibody ELISAs, which were 
conducted retrospectively, indicated that the animals had been previously exposed 
but uninfected at the point of experimental infection as determined by their antibody 
positive and antigen negative status at day 0.  It was decided to proceed with the 
experiment, as it was still possible to assess the antigen specificity of T cell 
responses in these calves. Isolation and characterisation of the BVDV virus found to 
be present in the supplier’s animals showed it to be closely related to BVDV Oregon 
C24V (APHA Mammalian Investigation Unit, personal communication), it was 
concluded that prior infection was unlikely to interfere with the assessment of T cell 
responses boosted by the experimental infection with BVDV Oregon C24V.  
Clinical scoring and rectal temperatures monitored to determine the outcome 
of experimental infection and some evidence of a mild acute BVDV infection was 
observed in some of the animals. One of the pre-exposed infected animals (C09-
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5016) showed evidence of dyspnoea and ocular discharge from 9 days post infection 
(dpi), while a second, calf C09-5018, had diarrhoea on 20-21 dpi, and the previously 
naïve animal that was experimentally infected (C09-5017) had ocular discharge 
between 10 and 17 dpi. Neither the naïve infected nor uninfected controls showed 
any significant clinical signs (Figure 3.1a). Median rectal temperatures for all the 
animals were normal (~38°C) throughout the observation period. Low levels of virus 
were detected by qRT-PCR from peripheral blood samples in animals C09-5017 and 
C09-5018, up to 49 dpi (Figure 3.1b). Virus was detected in the pre-exposed 
infected animals at 4 dpi, while virus was detected in the naïve infected animal at 11 
dpi and peaked at 23 dpi. Viral load was higher post-infection for the naïve infected 
animal (C09-5017) than those that had been pre-exposed but both groups had similar 
virus levels after the high-dose infection (>28 dpi). The control animals showed no 
evidence of virus infection throughout.  There were no differences in the mean white 
blood cell counts per μL (WBC/ μL) in the different animals after the primary and 
secondary infection (Figure 3.1c). 
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Table 3.1. BVDV antigen and antibody status of calves prior to experimental 
infection.  
 
Calf Tag No. 
Status post-
challenge* 
BVDV antibody 
(Antibody 
ELISA) 
 
BVDV antigen 
(Antigen 
ELISA) 
 
C09-5016 Pre-exposed infected + - 
C09-5017 Infected - - 
C09-5018 Pre-exposed infected + - 
C09-5020 Pre-exposed infected + - 
C09-5022
#
 Pre-exposed control + - 
C09-5025
#
 Control - - 
*All the animals were reported as BVDV antigen free prior to the experiment, but a 
number of the calves (n=3) in the group to be infected and one control calf were 
subsequently found to be pre-exposed to BVDV (antibody positive). 
#
Controls. 
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Figure 3.1. Outcome of primary (day 0) and secondary (day 28) experimental 
infections with BVDV-1a Oregon C24V. Calves pre-exposed to BVDV (pre-exposed 
infected, n=3) and a naïve calf (infected, n=1) were experimentally infected with 
BVDV-1a Oregon C24V, or uninfected control calf (control, n=1) were monitored 
for (a) clinical signs scored as the sum of 6 parameters, (b) rectal temperatures, (c) 
viraemia assessed by qRT-PCR and expressed as the BVDV RNA copy number/μl 
peripheral blood on a logarithmic scale (log) and (d) white blood cell counts were 
assessed by flow cytometry and expressed per μl blood (WBC/L). Data represented 
as means ± SEM. 
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3.2.2 BVDV antibody responses 
BVDV-specific antibodies were detected in the previously naïve animal 
inoculated with BVDV Oregon C24V from 21 dpi (Figure 3.2a), and levels 
continued to rise over the time-course studied up to 81 dpi. All the pre-exposed 
calves had high levels of BVDV specific antibody throughout the study period. The 
unexposed control animal was antibody negative. BVDV neutralising activity 
mirrored what was observed with total antibody with increase in titres from 21 dpi in 
the previously naïve animal while the previously exposed animals maintained fairly 
high titres (>640) from the onset of the experiment (Figure 3.2b). The unexposed 
control animal’s sera did not exhibit any neutralising activity.  
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Figure 3.2. BVDV-specific antibody responses following primary and secondary 
experimental infection with BVDV-1a Oregon C24V. (a) BVDV-specific serum 
antibody and (b), serum virus neutralisation titres in previously naïve infected, 
(infected, n=1), pre-exposed infected (n=3), pre-exposed control (n=1) and a naïve 
calf (control, n=1) calves following the experimental infection. 
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3.2.3 Detection of BVDV-specific T cell IFN-γ responses 
Ex vivo IFN-γ responses of PBMC to cytopathic BVDV Oregon C24V, as 
assessed by ELISA, showed responses by both infected and control calves (Figure 
3.3). The responding cells were characterised by flow cytometry after surface 
staining for lymphocyte surface markers (CD3, a co-receptor expressed on all T 
lymphocytes, CD8α/β and CD4, markers for CD8 and CD4 T lymphocytes 
respectively, CD335, a marker specific for natural killer cells and γδ-TCR, a marker 
of gamma-delta T cells) and intracellular staining for IFN-γ (Figure 3.3a). A large 
proportion of the IFN-γ response in the control calf was from CD4-CD8- cells while 
the infected animals showed larger proportions of CD4
+
 and CD8
hi
 IFN-γ+ cells 
(Figure 3.3b). One of the pre-exposed infected animals showed a higher response 
from CD8
lo
 cells that needs to be verified. Further analysis of the phenotype of the 
responses showed that a large proportion of the CD4
-
CD8
-
 response was from 
CD335
+ NK cells but not from γδ-TCR+ cells (Figure 3.3a). 
 In order to assess whether the IFN-γ stimulation observed in the naïve control 
animal was due to the virus used in the stimulation, cytopathic BVDV Oregon C24V 
(C24Vcp), cells from all the experimental animals were stimulated with a cytopathic 
(cp) and non-cytopathic (ncp) C24V virus pairs, C24cp and C24ncp, as well as a pair 
from BVDV W5, a BVDV-1 UK field strain (W5cp and W5ncp).  IFN-γ secretion 
was observed in the experimentally infected animals (C09-5016, 17, 18 and 20) after 
stimulation with all virus pairs as well as pokeweed mitogen (positive control) 
(Figure 3.4). IFN-γ reactivity in the naïve animal (C09-5025) was observed upon 
stimulation with both cytopathic and non-cytopathic C24V virus but not with the 
W5ncp and W5cp pair. We therefore believe that the stimulation of IFN-γ secretion 
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in the naïve animal is an effect specific to BVDV Oregon C24V regardless of the 
cytopathogenicity. This may be due to the attenuation of the virus for vaccination 
purposes but this effect was not investigated further in the context of this study. 
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Figure 3.3. Phenotyping of BVDV specific IFN-γ responses by flow cytometry. (a) 
Representative dot plots of virus stimulated PBMC showing proportions of IFN-γ+ cells 
from γδ T cell (γδ-TCR+), NK cell (CD335+), CD4+ T cell or CD8β+ T cell populations. 
The gating strategy involved viability and lymphocyte gating and assessment of IFN-γ+ 
cells in contrast to isotype control. Gating out of doublets was not possible because this 
feature was not enabled in the early versions of the flow cytometry software. (b) 
Proportion of IFN-γ+ γδ T cell (CD4-CD8α-), NK cell (CD4-CD8α-), CD4+ T cell or CD8β+ 
T cells following virus (closed bars) or mock (open bars) stimulation of PBMC from pre-
exposed infected calves (A) and the infected calf (B) compared to the control calves (C). 
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Figure 3.4 IFN-γ responses following stimulation with paired cytopathic and non-
cytopathic BVDV strains. IFN-γ responses from infected (16, 17, 18 and 20) and control 
(25) calves following stimulation with Pokeweed Mitogen (PWM), Media (Med), 
Cytopathic (cp) and non-cytopathic (ncp) BVDV C24V and W5 viruses.  
  
3.2.4 Quality control of BVDV peptide library 
Reconstituted 16-mer peptides were pooled to represent the individual viral 
proteins of BVDV-1a Oregon C24V. Due to their large number, peptides 
representing NS3 and NS5B were each prepared in two pools.  To assess any 
potential cytotoxic effects of the peptide pools and or the solvent used to reconstitute 
them, PBMC were cultured for 24 hours with peptide pools containing each peptide 
at 2μg/ml. Cultured PBMC were stained with near infra-red live/dead viability stain 
and analysed by flow cytometry to determine the proportion of live cells. The results 
showed that none of the peptide pools resulted in a loss of cell viability compared to 
cells cultured alone in complete RPMI (Figure 3.5a). The peptide pools were also 
found not to induce non-specific IFN-γ responses in PBMC from BVDV naïve 
animals, which were exposed to Mycobacterium bovis and therefore responded to 
tuberculin purified protein derivative (PPD) and to pokeweed mitogen (PWM) as 
assessed by IFN-γ ELISA (Figure 3.5b).  
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Figure 3.5. Quality control of BVDV peptide pools. (a) Proportion of viable cells 
after 72-hour culture of naïve PBMC with peptide pools or without peptides (media) 
as assessed by Live/Dead viability dye (n=1). (b) IFN-γ responses of PBMC from 
five BVDV naïve, tuberculin-reactor animals (n=4) to peptide pools, tuberculin PPD 
and PWM as positive controls. 
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3.2.5 Assessment of antigen-specificity of T cell responses 
BVDV T cell responses to peptide pools were assayed by bovine IFN-γ 
ELISA and longitudinal responses from the experimentally infected animals up to 81 
dpi are shown in Figure 3.6. Responses to peptide pools representing non-structural 
and structural proteins are shown in Figures 3.6a and b, respectively. The greatest 
responses were observed to the E2 and the NS3-II pool, with represents the C-
terminal helicase domain of NS3, which were found to be statistically significant in 
comparison to the control (p>0.01, p<0.05 respectively) overall (Figure 3.6c). Lesser 
responses were additionally observed against pools representing the E
rns
, NS2 and 
NS4B proteins. IFN-γ responses to peptide pools were detected 28 days after the 
secondary infection (56 dpi) and responses were still detectable at 153 dpi in the 
infected animals while the control did not mount a statistically significant (Figure 
3.6c) IFN-γ response to any peptide pool. There were no significant differences in 
the peptide IFN-γ responses to peptide pools between the pre-exposed infected calves 
and the calf that was naive prior to experimental infection.  The responses to the 
various peptides pools were observed even after 351 dpi but with greater breadth in 
the previously naïve calf (5017) compared to the pre-exposed calves (5016, 5017 and 
5019). No responses were observed in the naïve control animal (5025) (Figure 3.7). 
 
3. T cell responses to BVDV 
 
 59 
 
Figure 3.6. BVDV antigen-specific IFN-γ responses following primary and 
secondary experimental infections with BVDV Oregon C24V. Longitudinal IFN-γ 
responses of PBMC to peptide pool representing (a) structural and (b) non-structural 
proteins are presented as the mean media-corrected OD values (test OD minus media 
OD) for all the infected calves (n=4). (c) Responses to peptide pools and live BVDV 
(MOI=5) at 153 dpi in the infected (n=4) and uninfected control calf (n=1). PWM or 
complete RPMI (Med)/mock virus supernatant served as positive and negative 
controls respectively. Error bars represent SEM. (** = p<0.01, * = p>0.05 in the 
infected compared to the control)
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Figure 3.7. IFN- responses to BVDV peptide pools after one year (351 days post infection). Responses in pre-exposed infected (5016, 5018 
and 5020), previously naïve infected (5017) and BVDV naïve (5025) calves. 
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3.2.6 Phenotype of BVDV Specific T cell Responses 
 
Ex vivo responses of PBMC from the experimentally infected calves to 
peptide pools were not possible to resolve with the original protocol that included an 
overnight incubation with peptides followed by 4-hour incubation with brefeldin A. 
However, low frequency CD4
+ 
IFN-γ responses were seen for the E2 and NS3 
peptide pools after optimisation of the assay to 2 hour incubation with peptides prior 
to 12 hour incubation with brefeldin A as shown in Figure 3.8. There were no 
observable CD8 T cell responses using this method.  No systematic optimization of 
the intracellular cytokine staining (ICS) was conducted and we recommend further 
optimization of these assays to detect peptide-specific responses. It has been 
suggested that the duration of antigen-stimulation and subsequent brefeldin A 
incubation also alter the diversity of multifunctional T cells measured by intracellular 
cytokine staining (Kaveh et al., 2012). 
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Figure 3.8. Phenotype of ex vivo IFN-γ responses to BVDV E2 and NS3 peptide 
pools. IFN-γ responses of PBMC from infected calf C09-5017 were assessed by flow 
cytometry following incubation of cells with brefeldin A. Viable lymphocytes were 
gated (gating strategy as shown in Figure 3.4) and the proportion and total numbers 
of cells of CD4
+
 IFN-γ+ cells as presented. PWM and media were used as positive 
and negative controls respectively while irrelevant mouse IgG1 antibody (isotype 
control) was used to control for the IFN-γ staining.  
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3.3 DISCUSSION 
Assessment of immune responses after recovery from an acute infection is 
thought to be a good model for the induction of immunity since it mimics acquisition 
of natural immunity and there is no bias expected in the antigens that are available 
for presentation to the immune system. Rechallenge of the animals with the 
homologous virus allows the assessment of which of the responses induced by the 
primary infection are effectively recalled and thus may constitute protective 
responses. 
Although four out of the six experimental animals were found to have been 
pre-exposed to BVDV prior to inclusion in this study, it was possible to demonstrate 
BVDV specific IFN-γ responses following experimental infection. Serological typing 
and phylogenetic analyses of the prevalent BVDV strains from where the animals 
were sourced showed that they are closely related to BVDV-1a Oregon C24V 
(Mammalian Virus Investigations Unit, APHA). The effect of pre-exposure to 
BVDV is difficult to explore in this set up, as the nature of the previous exposure is 
not known. Pre-exposure has been reported to modulate immune responses in other 
related viral infections such as hepatitis C virus infection, where, sub-infectious 
exposure has recently been shown to suppress T cell responses following subsequent 
acute infection (Park et al., 2013).  In this study, it was shown that previous exposure 
in rhesus monkeys to HCV resulted in diminished T cell responses following viral 
challenge.  
The outcome of infection was mild/sub-acute as expected following infection 
with BVDV-1a Oregon C24V, which has previously been used as a live attenuated 
vaccine (Coggins et al., 1961). Antibody responses, as detected by ELISA, were seen 
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3 weeks after the low dose infection and may have contributed to the suppression of 
viraemia after the high dose infection. The higher peak in virus in the infected calf 
compared to the pre-exposed infected calves after the primary infection maybe due to 
pre-existing antibodies in the latter group.  
Longitudinal analysis of ex vivo BVDV-specific T cell IFN-γ responses by 
ELISA showed clear responses to peptide pools after the second experimental 
infection, suggesting that the high dose virus infection was required for recruitment 
and expansion of antigen specific T cells as previously described (van Heijst et al., 
2009). A low frequency of CD4
+
 but not CD8
+
 IFN-γ secreting cells to E2 and NS3 
peptide pools was observed in PBMC from the infected calves possibly reflecting the 
low frequency of responders in vivo, a result that would need to be confirmed after 
further optimisation of the intracellular cytokine assay.  
IFN-γ responses of PBMC, from both naïve and experimentally infected 
calves, after stimulation with cytopathic BVDV C24V, were shown to include non-
specific/innate NK responses. There is a need to better characterize virus-specific 
responses from naïve versus infected animals and compare NK cell responses 
between non-cytopathic and cytopathic BVDV virus pairs. Ex vivo responses to 
BVDV peptide pools showed E2 and NS3 are the immunodominant proteins, while 
responses to other proteins such as E
rns
 and NS4B were also observed albeit not with 
statistical significance. However, to validate these findings, there is need to repeat 
this experiment with additional calves. 
The determination of the fine-specificity of these responses was not done 
given the limited sample size, undetermined major histompatibility complex (MHC) 
background of the animals and previous exposure to BVDV. It is however hoped that 
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this study will inform further studies aimed at identifying minimal length peptides 
and epitopes in the various BVDV proteins that have been shown to be targets of T 
cell responses. This would employ the use of peptide matrix pools to identify 
individual peptides stimulating responses and to map T cell epitopes (Roederer and 
Koup, 2003) as well as the establishment of T cell lines in order to maintain and 
expand the frequency of antigen specific T cells (Hart et al., 2011b). The phenotype 
of responding T cells (CD3
+
CD8β+ or CD3+CD4+) can also be determined by either 
magnetic activated cell sorting (MACS) of specific cell populations prior to 
stimulation or by multiparametric flow cytometry. Staining for activation markers 
such as CD25 and CD26, and memory markers (CD45RO, CD62L) may also be 
useful in distinguishing cells in different activation states and distinguish naïve from 
central or effector memory cells. There is also a need to assay for additional cytokine 
responses by multiplex ELISA or intracellular staining for a broader array of 
cytokines such as TNF-α, IL-2 and IL-4, measure proliferative responses and 
cytotoxic activity by granzyme B or perforin staining or cytotoxicity assays with 
virus infected cells as targets.  
 Given that only a relatively small number of cattle will be utilised in this 
process, it is proposed to test the recognition of identified targets by T cells from a 
much larger group of cattle that have been exposed to BVDV in the field. This 
analysis would validate which of the identified antigens are the dominant targets and 
thus be good candidates for evaluation of their immunogenicity in vaccine 
experiments. Furthermore, an understanding of the fine specificity of these responses 
will enable an analysis of polymorphism affecting these epitope-encoding regions 
that has significant implications for subsequent subunit vaccine design. It also may 
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simplify potential vaccine formulations if only relevant portions of proteins are 
required to be expressed and formulated rather than the corresponding full-length 
proteins.
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4 COMPARATIVE ANALYSIS OF IMMUNE RESPONSES 
FOLLOWING INFECTION WITH BOVINE VIRAL DIARRHOEA VIRUS-1 
AND AN ASIATIC ATYPICAL BOVINE PESTIVIRUS 
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SUMMARY 
Bovine viral diarrhoea virus (BVDV) exists in two recognized species, 
BVDV-1 and BVDV-2, and closely related atypical bovine pestiviruses have recently 
been described. While there is evidence of cross-protective immune responses 
between BVDV-1 and BVDV-2 virus strains in spite of antigenic differences, there is 
little information on the antigenic cross-reactivity between BVDV-1 and atypical 
bovine pestiviruses. The aim of this study was to assess whether antibody and T cells 
induced by one virus were capable of responding to heterologous virus and identify 
possible targets of cross-reactive or species-specific responses. Three to five month 
old calves were infected with BVDV-1a strain Horton-916 (Ho916), 
Th/04_KhonKaen (TKK), an Asiatic atypical bovine pestivirus strain, or co-infected 
with both. Antibodies against E2 were detected in all infected groups, but to a lower 
extent in the TKK infected animals. Homologous virus neutralization was observed 
in sera from both single virus infected and co-infected groups, while cross-
neutralization was only observed in the TKK infected group to Ho916 virus. T cell 
IFN-γ responses to both viruses were observed in the TKK infected animals, whereas 
Ho916 infected calves responded better to homologous virus. Specifically, IFN-γ 
responses to NS3 were observed in all infected groups while responses to E2 were 
virus specific. Broader cytokine responses were observed with similar trends 
between inoculation groups and virus species. Overall, infection of cattle with TKK 
virus appeared to induce antibody and T cell responses that exhibited a greater 
degree of cross-reactivity and recognition of Ho916 virus that suggests that 
conserved targets of immune responses may be shared with a common archetypical 
virus ancestor.  
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4.1 INTRODUCTION 
The Pestivirus genus within the Flaviviridae family of single stranded 
positive sense RNA viruses comprises four recognized species: Bovine viral 
diarrhoea virus 1 (BVDV-1) and 2 (BVDV-2), classical swine fever virus (CSFV) 
and border disease virus (BDV), (Simmonds et al., 2011). Additionally, five groups 
of unclassified pestiviruses have also been discovered: Tunisian sheep virus (TSV), 
pestivirus of giraffe, Pronghorn antelope virus, Bungowannah and atypical bovine 
pestiviruses, the last four of which have been proposed as additional Pestivirus 
species. 
Pestiviruses are genetically and antigenically related with evidence of both 
cross-reactive monoclonal antibody (mAb) epitopes and serological cross-reactivity 
(Simmonds et al., 2011). Current classiﬁcation of pestiviruses is based on genetic and 
serological relatedness as well as the host of origin. Phylogenetic analyses based on 
the 5’ untranslated region (5’UTR), the amino-terminal proteinase, Npro, and the 
major envelope glycoprotein, E2, sequences allow delineation of individual species. 
Genetic relatedness of pestiviruses has been shown to be consistent with antigenic 
relatedness as defined by binding assays with mAbs or serum cross-neutralization 
relative to the type virus of a particular species (Becher et al., 2003). 
Atypical bovine pestiviruses, which form a monophyletic clade with a sister 
relationship to BVDV-1 and 2, have been detected in contaminated foetal bovine 
serum (FBS) and in natural infections in bovines (cattle and buffalo). These include: 
D32/00_HoBi, isolated from an FBS batch originating from Brazil (Schirrmeier et 
al., 2004); Brz buf 9,  isolated from a buffalo in Brazil (Stalder et al., 2005); CH-
KaHo/cont, a cell culture contaminant possibly from a South American FBS batch; 
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‘Hobi’-like viruses detected in aborted bovine foetuses in Brazil (Cortez et al., 2006); 
Th/04_KhonKaen, detected from serum of a naturally infected calf in Thailand (Ståhl 
et al., 2007); SVA/cont-08, a viable pestivirus detected in a batch of FBS from South 
America (Liu et al., 2009b); and IZSPLV_To, isolated from FCS (Peletto et al., 
2010).  More recently, a ‘Hobi’-like Pestivirus, Italy-1/10-1, has been associated with 
a severe respiratory disease outbreak and abortions in multiparous cows in Italy 
(Decaro et al., 2011b, Decaro et al., 2011a). While there is evidence suggesting that 
atypical bovine pestiviruses are already spread in cattle in South America (Cortez et 
al., 2006), southeast Asia (Ståhl et al., 2007) and recently in Europe (Decaro et al., 
2011a), there is a need for broader surveillance to assess the extent to which they are 
spread in the cattle population worldwide and the possible impact on current BVDV 
control programs. 
Genetic and antigenic diversity between bovine pestiviruses poses a 
significant challenge in BVDV diagnosis and vaccination (Bolin and Grooms, 2004). 
Diagnosis by detection of viral material (nucleic acid or antigen) or through 
quantification of virus specific immune responses can be hampered by the variability 
within these targets making it difficult to recognise divergent or atypical viruses. 
Furthermore, limited virus cross neutralization and the limited detection of atypical 
pestivirus antibody using commercial BVDV antibody ELISA (based on BVDV-1) is 
evidence of significant antigenic diversity between atypical pestiviruses and BVDV-
1 and -2 (Schirrmeier et al., 2004, Ståhl et al., 2007, Bauermann et al., 2012). This 
also raises questions regarding the potential efficacy of existing BVDV vaccines 
against these novel viruses. Whilst clinical cross protection against BVDV-2 
challenge has been reported using BVDV-1 based vaccines, vaccination failure due 
to inadequate protection from foetal infection, postnatal infection and virus shedding 
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is often attributed, in part, to virus diversity (Bolin and Grooms, 2004). In future, 
vaccines will have to be designed with responses to different BVDV-1 and 2 
subgenotypes as well as atypical bovine pestiviruses in mind, by inclusion of the 
different virus genotypes or identification of targets of cross reactive immune 
responses, or by the use of species specific vaccines.  
This study, conducted as part of an experiment comparing the infection 
kinetics of calves with a BVDV-1a virus (Horton 916), an Asiatic atypical bovine 
pestivirus (Th/04_Khon_Kaen) or co-infection with both viruses, aimed to assess 
whether antibody and T cell responses induced by one virus were capable of 
responding to the heterologous virus and to determine if the immunodominant 
proteins, E2 and NS3, identified in Experiment 1 (Chapter 3) are targets of cross-
reactive or distinct species-specific responses.  
This work was conducted as part of an EPIZONE Internal Call funded 
Project, ‘Comparative dynamics of BVDV (IC 6.8)’, a collaborative project between 
the Swedish University of Agricultural Sciences/National Veterinary Institute 
(SLU/NVI), Uppsala, Sweden, the National Veterinary Institute (PIWET), Puławy, 
Poland and the APHA, Surrey, UK. EPIZONE European Research Group (ERG) is a 
European network of veterinary research institutes working on epizootic animal 
diseases. I received a travel award to SLU/NVI and PIWET as the APHA 
collaborator and was involved in the planning and execution of the experiment and 
the immunological analyses.  
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4.2 RESULTS 
 
4.2.1 Outcome of experimental infection 
Three to five month old calves were infected with BVDV-1a strain Horton-
916 (Ho916), Th/04_KhonKaen (TKK), an Asiatic atypical bovine pestivirus strain, 
or co-infected with both (n=5 per group). The clinical and virological outcome 
following inoculation with Ho916 and TKK or co-infection with both (Ho916/TKK) 
are reported elsewhere (Larska et al., 2012) (Appendix A) and summarised in Table 
4.1. Whilst leucopoenia and lymphopoenia, assessed by complete blood cell counts, 
were observed to similar extents in all infected groups coinciding with the onset of 
viraemia, milder clinical signs were observed in the TKK group. Co-infection 
resulted in prolonged elevated temperatures in comparison to the singular infection 
with the Ho916 or TKK viruses. Similar courses of viraemia as determined by 
nucleic acid detection by qPCR and viral antigen detection by ELISA were 
determined in all three infected groups. Simultaneous detection of both viruses in 
blood and nasal swabs was observed in the co-infected group (Ho916/TKK). All 
inoculated groups seroconverted two weeks after inoculation as assessed by serum 
neutralisation of homologous virus. 
 
4.2.2 Detection of E2 and NS3 specific antibodies by ELISA 
All infected groups mounted a significant E2 specific antibody response from 14 
dpi (Figure 4.1a) as determined by a competitive BVDV ELISA. Percent inhibition 
values in the Ho916 and Ho916/TKK groups exceeded the assay diagnostic cut-off 
for positivity from 14 dpi. While the E2 specific antibody levels in the TKK group 
increased from 14 dpi they were not above the cut-off until 21 dpi. The E2 specific 
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antibody levels of the Ho916 and Ho916/TKK groups were significantly greater than 
in the TKK group from 14 dpi. The Ho916 and Ho916/TKK groups showed NS3 
antibody responses (Figure 4.1b) from 21 dpi compared to the control group, whilst 
the TKK group responses were significant compared to the controls from 28 dpi but 
did not exceed the diagnostic cut-off for assay positivity until 35 dpi. Ho916 group 
responses were significantly greater than the TKK group at 21 (p<0.0001) and 28 dpi 
(p<0.001), whereas, Ho916/TKK antibody levels were significantly greater than 
TKK between 14 and 35 dpi (p<0.001). There were no significant differences in NS3 
responses between Ho916 and Ho916/TKK groups. 
A serial dilution of sera (1:4 – 1:64) was assayed for both E2 and NS3 antibodies 
at 42 dpi in order to resolve possible quantitative differences in antibody levels that 
were obscured by assay saturation at the recommended sera dilution (Figure 4.1c). 
E2 antibodies were detected in Ho916 and Ho916/TKK groups at serum dilutions of 
1:4 to 1:64, and responses in the TKK group were significantly lower, only being 
above the assay cut-off up to a dilution of 1:8. At the same time point, percent 
inhibition values for NS3 antibodies from all infected groups were above the cut-off 
up to the final dilution of 1:64 (Figure 4.1d). 
 
74 
 
Table 4.1. Outcome and kinetics of experimental infection with Ho916 and TKK viruses 
  Ho916 TKK Ho916/TKK 
Parameter of infection Days post infection (dpi) 
Pyrexia   7-9 7-10 7-12 
Leukopoenia   2-7, 14* 5-9 2-7, 14* 
Lymphopoenia    2-7, 14* 2-7 2-7, 14* 
Clinical signs 
5-14 (diarrhoea, coughing, nasal 
and ocular discharge) 
7-21 (coughing, nasal and 
ocular discharge) 
7-14 (diarrhoea, coughing, nasal and 
ocular discharge) 
Viral antigen (E
rns 
Ag ELISA)    2-7 2-7 2-7 
Viral RNA in PBMC (qPCR) 2-28 5-28 2-28**, 5-28*** 
Virus isolation from PBMC  (IPX)  5-9 5-9 7-9 
Virus RNA from nasal swabs (qPCR)  5-9, 21 2-21 5-14**, 2-21*** 
Virus isolation from nasal swabs  (IPX)  5-7 5-7 5-9 
Seroconversion (VNT)****  14 14 14 
*Biphasic; **BVDV-1 specific real time RT-PCR (Baxi et al., 2006); ***atypical bovine pestivirus specific real time RT-PCR  (Liu et al., 2008), 
**** Neutralization against BVDV-1d and TKK virus  
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Figure 4.1. E2 and NS3 specific antibody responses of calves following 
experimental infection with BVDV-1 Ho916, atypical bovine pestivirus TKK, co-
infection with both (Ho916/TKK) or uninfected controls. Longitudinal antibody 
responses were measured by competitive ELISA against BVDV E2 (a) and NS3 (b) 
proteins. Responses at 42 days post infection, were assessed using a serial dilution of 
serum (1:4 – 1:64) against E2 (c) and NS3 (d). Antibody levels were calculated as % 
inhibition (PI) of antigen specific mAb binding, and dashed lines denote positivity 
cut-off for the respective assays. Data represented as means ± SEM. 
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4.2.3 Measurement of virus-neutralising antibody titres 
A comparison of homologous and heterologous neutralization activity of both 
viruses by sera from the different experimental groups was conducted in order to 
assess the antigenic relatedness of the viruses. Homologous neutralization of both 
Ho916 and TKK viruses was observed from 14 dpi in the single and co-infected 
groups (Table 4.1). However, neutralization of Ho916 virus by sera from TKK 
inoculated cattle only occurred at low titres at 42 dpi while neutralization of TKK 
virus by Ho916 inoculated animals’ sera was observed from 21 dpi but also at low 
titre (Larska et al., 2012). Ho916 virus neutralization titres in both Ho916 and 
Ho916/TKK group sera were higher than the TKK group sera and a similar pattern 
was observed against BVDV-1a C24V but with lower titres (Figure 4.2a). In 
contrast, TKK virus was neutralized by TKK and Ho916/TKK inoculated group sera 
but not by the Ho916 inoculated animals’ sera. Neutralization of BVDV-2 was 
observed at low titres in all inoculated groups with the lowest titres in sera from 
Ho916 inoculated animals. BDV was better neutralized by Ho916 and Ho916/TKK 
group sera compared to sera from the TKK inoculated animals. Assessment of cross-
neutralisation, calculated as the percentage of heterologous versus homologous 
neutralization, showed that despite exhibiting weaker homologous neutralization, 
TKK group sera showed comparatively good neutralization of Ho916, C24V and 
BVDV-2. (Figure 4.2b) Ho916 group sera showed significant cross neutralization of 
C24V albeit with lower titres compared to homologous neutralization. While cross-
neutralization of all other viruses by sera from the Ho916 inoculated animals was 
considerably less than homologous virus neutralization. Cross-neutralization of 
BDV-1 by sera from all inoculation groups was poor. 
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Figure 4.2. Homologous and heterologous virus neutralising antibody responses of 
calves experimentally infected with BVDV-1 Ho916, atypical bovine pestivirus 
TKK, co-infection with both (Ho916/TKK) or uninfected controls. (a) Neutralising 
titres of serum pools collected at 42 dpi from the different infection groups against 
Ho916, TKK, BVDV-1a Oregon C24V (C24V), BVDV-2 502643 (BVDV-2) and 
BDV-1 S137/4 (BDV). (b) Cross-neutralization of heterologous virus was calculated 
as a percentage of homologous neutralization of Ho916 virus by TKK inoculated 
cattle (PH>T), TKK virus by Ho916 inoculated cattle (PT>H) as well as cross 
neutralization of C24V (PC24V), BVDV-2 (P2), or BDV-1 (PBDV) by either Ho916 or 
TKK sera.  
4.2.4 
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BVDV sequence analysis 
Sequence comparison of Ho916 and TKK translated E2 protein sequences 
revealed significant divergence between Ho916 and TKK (57.2% divergence, 59.2% 
identity) in comparison to Ho916 and the reference BVDV-1 C24V strain (14% 
divergence, 87.3% identity) (Figure 4.3a). The NS3 protein however was more 
conserved between the different viruses with 8.4% divergence, 90.5% identity 
between Ho916 and TKK and 1.4% divergence and 96.9% identity between Ho916 
and C24V (Figure 4.3b).  
 
4.2.5 Measurement of virus specific cytokine responses by IFN-γ ELISA and 
multiplex assay 
4.2.5.1 IFN-γ responses 
In comparison to uninfected controls, significant ex vivo PBMC IFN-γ 
responses were observed against Ho916 and TKK viruses from 28 dpi. PBMC from 
the Ho916 inoculated group stimulated with Ho916 virus showed significant IFN-γ 
responses on 35 (p<0.05) and 42 (p<0.01) dpi, whilst responses in the TKK group 
were only significant at 42 dpi (p<0.01) (Figure 4.4a). Responses to Ho916 virus in 
the Ho916/TKK group were less than in the other two infection groups and were not 
statistically significant. Responses to the TKK virus on the other hand, were 
significant in both the TKK and Ho916/TKK groups at 28 and 35dpi (Figure 4.4b). 
Responses to the TKK virus by PBMC from the Ho916 group were not statistically 
significant.  
Responses to E2 peptide pools at 42 dpi followed similar trends to the 
responses to virus (Figure 4.4c). IFN-γ responses to the E2 peptide pool representing 
Ho916 virus (E2-Ho916) were observed in the Ho916 and Ho916/TKK groups but 
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not in the TKK group. Responses to E2-TKK peptide pool were seen in the TKK and 
Ho916/TKK groups albeit only statistically significant in the TKK group (p<0.01). 
Responses to the NS3 peptide pool (Figure 4.4d) were observed in all infected 
groups and were statistically significant in the Ho916 (p<0.05) and TKK (p<0.001) 
infected groups.  
 
4.2.5.2 Detection of cytokines by multiplex assay 
A number of cytokines and chemokines associated with cell-mediated 
responses (Coad et al., 2010) were assessed following ex vivo stimulation of PBMC 
with virus or peptides. These cytokines and chemokines were already available for 
detection using a custom multiplex ELISA assay (Coad et al., 2010). Broad 
responses were observed following virus (Figure 4.5) and peptide (Figure 4.6) 
stimulation. As with IFN-γ, the significance of cytokine levels in the different 
infection groups was assessed in comparison to the control group. TKK infected 
animals were observed to elicit a broad cytokine response following stimulation with 
homologous virus, as well as heterologous virus. Significant quantities of IL-4, IL-
10, IL-12, IL-1β, IL-6 and MIP-1β were secreted by PBMC from TKK infected 
animals following TKK and Ho916 stimulation. With the exception of MIP-1β, 
which is secreted primarily by CD8
+
 T cells, the other cytokines were not secreted to 
significant levels in the Ho916 infected animals following stimulation with the TKK 
virus. IL-12 secretion, typically associated with dendritic cells and macrophages, was 
observed in response to the Horton 916 virus in all infection groups. However, this 
was not the case with the TKK virus, which induced only a weak IL-12 response in 
the co-infected group that was not statistically significant. While IL-4 production 
was observed at lower levels in the co-infected animals in response to both viruses, 
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IL-10, IL-6 and MIP-1β were secreted in significant levels in this group following 
TKK stimulation. IL-1β responses in the co-infected animals were significant 
following TKK stimulation, and also observed following Ho916 stimulation, 
although not significantly so.  
Significant IL-4 responses to the E2 peptide pool from the Ho916 virus (E2-
Ho916) were observed in the Ho916 virus and co-infected groups and to the NS3 
C24V peptide pool in the co-infected group but not against E2-TKK in any of the 
infected groups. IL-10 responses against NS3 and E2-TKK peptide pools were 
observed in the Ho916 infected group, and against E2-TKK peptide pool in the TKK 
infected group while the co-infected group had significant responses to both E2 
peptide pools and NS3. IL-12 responses were only significant against NS3 in the co-
infected group, while IL-1β responses were significant after stimulation with E2-
TKK in the TKK and co-infected groups and to NS3 in all infected groups. IL-6 
responses against E2-Ho916 were significant in the Ho916 group and to E2-TKK 
and NS3 in the TKK group. MIP-1β responses were significant in all infected groups 
to E2-Ho916 and NS3 and to E2-TKK in the TKK and co-infected groups. 
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Figure 4.3. Alignment of translated E2 (a) and NS3 (b) protein sequences from 
BVDV-1 Ho916, atypical pestivirus TKK and BVDV-1 reference strain C24V. 
Sequences were aligned using clustalw and distances calculated from construction of 
phylogenetic tree (PAM250) on MegAlign (DNA Star Inc.). Sequence distances are 
shown in tables. 
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Figure 4.4. IFN-γ responses of calves following experimental infection with BVDV-
1 Ho916, atypical bovine pestivirus TKK, co-infection with both (Ho916/TKK) or 
uninfected controls. Longitudinal PBMC IFN-γ responses following stimulation with 
Ho916 (a) and TKK (b) viruses were measured by ELISA and adjusted for mock 
stimulated background responses. PBMC isolated 42 dpi were stimulated with 
synthetic peptide pools representing E2 protein from Ho916 (E2-Ho916) and TKK 
(E2-TKK) (c) and NS3 protein from C24V (d), and IFN-γ production measured by 
ELISA and adjusted for background response of unstimulated cells. Data represented 
as means ± SEM (a and b) or box and whisker plots (c and d) and statistical 
significance is denoted by * (p<0.05), ** (p<0.01), *** (p<0.001) and **** 
(p<0.0001). 
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Figure 4.5. Assessment of virus-specific cytokine responses following experimental 
infection with BVDV-1 Ho916, atypical bovine pestivirus TKK, co-infection with 
both (Ho916/TKK) or uninfected controls. PBMC isolated at 42 dpi were stimulated 
with Ho916 or TKK viruses and secretion of IL-4 (a), IL-10 (b), IL-12 (c), IL-1β (d), 
IL-6 (e) and MIP-1β (f) measured by a multiplex assay. Data represented as means ± 
SEM and statistical significance denoted by, * (p<0.05), ** (p<0.01) and *** 
(p<0.001). 
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Figure 4.6. Assessment of antigen-specific cytokine responses following 
experimental infection with BVDV-1 Ho916, atypical bovine pestivirus TKK, co-
infection with both (Ho916/TKK) or uninfected controls. PBMC isolated at 42 dpi 
were stimulated with peptide pools representing the Ho916 (E2-Ho916) and TKK 
(E2-TKK) E2 protein and NS3 protein from C24V and secretion of IL-4 (a), IL-10 
(b), IL-12 (c), IL-1β (d), IL-6 (e) and MIP-1β (f) measured by a multiplex assay. 
Data represented as means ± SEM and statistical significance denoted by, * (p<0.05), 
** (p<0.01) and *** (p<0.001). 
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4.3 DISCUSSION 
Recent disease outbreaks within the EU caused by atypical bovine 
pestiviruses have highlighted a group of viruses that have thus far received little 
attention. A recent study of atypical pestiviruses in FBS batches from different 
countries also suggests greater intercontinental spread/distribution than previously 
anticipated (Xia et al., 2011). Comparative analyses of antigenic relationships 
between atypical bovine pestiviruses and BVDV-1 and BVDV-2 point towards the 
need for improved diagnostics and reformulation of current vaccines for the detection 
and control of these new viruses (Bauermann et al., 2012). This study aimed to 
increase understanding of the implications of antigenic diversity on both T cell and 
antibody responses to BVDV and atypical pestiviruses.  
In this study, both E2 and NS3 specific antibody responses were detected in 
all infected groups two to three weeks post infection albeit to a lesser extent in the 
Th/04_KhonKaen group. This raises questions about the sensitive detection of 
antibodies against atypical bovine pestiviruses, such as Th/04_KhonKaen, by 
diagnostic ELISA assays designed to detect antibodies typically against BVDV-1. 
Moreover, limited detection of antibodies to a European atypical bovine pestivirus, 
Italy-1/10–1, using a commercial BVDV-1-based ELISA, despite high neutralization 
titres has recently been described (Decaro et al., 2011a). In the present study, NS3 
antibodies were better detected than antibodies against the less conserved E2 protein. 
NS3 antibodies were detected above the detection cut-off in all infected animals 
using a blocking ELISA kit (SVANOVIR® BVDV p80, Svanova Biotech AB) 
capable of recognizing antibodies against BVDV-1, 2 and ‘HoBi-like’ atypical 
bovine pestivirus according to the manufacturer. An alternative multispecies (BVDV 
and BDV) NS3 assay (Pourquier® ELISA BVD p80, Institut Pourquier, Montpellier, 
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France) which is known to use pan-pestivirus NS3 mAbs WB103 and peroxidase 
coupled WB112 (Edwards et al., 1988) as the capture and detection antibodies 
respectively. It has recently been proposed that diagnostics for BVDV and atypical 
pestiviruses should be based on NS2/3 or E
rns
 which bear good cross reactive targets 
while assays targeting E2 may allow discrimination of pestivirus species (Bauermann 
et al., 2012). This is in agreement with our observation of greater cross-reactivity in 
responses against NS3 relative to responses to E2 which were generally virus strain-
specific.  
Here, homologous neutralization was observed in all infected groups, yet 
cross-neutralization was only observed against the Horton 916 virus in the 
Th/04_KhonKaen infected group, whose sera was able to neutralize the Horton 916 
virus almost to the same extent as the homologous virus. The relatively low 
homologous neutralizing antibody titres against Th/04_KhonKaen however, are 
suggestive of an inferior antibody response compared to the more robust titres in the 
Horton 916 infected and the co-infected groups. Similar patterns were observed with 
BVDV-1a NADL, routinely used in virus neutralization tests, while another atypical 
Pestivirus, D32/00_HoBi virus had similar neutralization patterns as the 
Th/04_KhonKaen virus. Patterns of cross neutralization of other bovine pestiviruses 
suggest that BVDV-1 is more similar antigenically to BDV-1 than atypical bovine 
pestiviruses, while closer similarity in neutralization was observed against BVDV-2. 
Limited cross neutralization activity, alluding to significant antigenic differences 
between BVDV-1 and 2 and atypical bovine pestiviruses have been previously 
reported (Schirrmeier et al., 2004, Ståhl et al., 2007).  
A degree of cross-reactivity of T cell responses in Th/04_KhonKaeninfected 
animals after re-stimulation with Horton 916 virus was observed. However, IFN-γ 
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responses to Th/04_KhonKaen however, were not observed in the Horton 916 
infected group. IFN-γ responses to E2 peptide pools were virus species specific 
whilst responses to the more conserved NS3 target appear to be maintained, to 
different extents, in all the infected groups.  
Analysis of broader cytokine responses showed differential induction of 
several cytokines in the infection groups suggestive of a possible modulation of 
responses to either of the viruses. The lack of cytokine responses in Horton 916 
infected animals following heterologous virus stimulation may hint at loss of T cell 
epitopes that may otherwise elicit cross-reactive responses. Broader cytokine 
responses however, were observed, in the Th/04_KhonKaen infected animals. IL-12 
production, which is important in inducing and maintaining Th1 cell responses, was 
observed in response to the Horton 916 virus but not the Th/04_Khon_Kaen virus. 
This may, in part, explain the differences in T cell responses to the two viruses but 
this observation needs to be investigated further.  Cytokine responses to E2 and NS3 
peptide pools followed similar trends to IFN-γ. Responses to E2-Ho916 were not 
observed in the TKK infected group, with the exception of MIP-1β and to some 
extent, IL-6. Similarly, responses to E2-TKK were, by large, absent in the Horton 
916 group, while as observed with IFN-γ, a number of cytokine responses were 
observed to the NS3 peptide pool in all the infected groups. These observations, 
taken together, point towards E2 responses being virus specific, with responses to the 
NS3 antigen being better conserved between the viruses. However, it is not clear 
what implications these differences in cytokine responses may have had, if any, on 
clinical and virological outcomes of infection with these viruses. This may be 
investigated better by transcriptomic profiling of host responses following infection 
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with the different viruses to elucidate differences in induction of host responses that 
may result in the different cytokine profiles.  
The limited T cell and antibody immune reactivity of Ho916 inoculated 
animals to Th/04_KhonKaen suggests that animals vaccinated with BVDV-1-based 
vaccines may not be protected against atypical bovine pestiviruses. Alignment of 
translated E2 and NS3 sequences from BVDV-1 Horton 916, a reference BVDV-1 
Oregon C24V and Th/04_KhonKaen confirmed greater genetic diversity in the E2 
sequences compared to the NS3 sequences. E2 antigenic variation is pronounced 
among BVDV viruses and is thought to contribute to vaccine failure. Domains 
associated with neutralizing epitopes have been mapped to a hypervariable region 
located in the N-terminus of the E2 protein (Paton et al., 1992, Deregt et al., 1998). 
The extent of variation in E2 is better appreciated amongst BVDV-1 viruses because 
of the availability of a large sequence dataset; there is however a need to generate 
more E2 sequence data from atypical pestiviruses to enable a more robust 
comparison. NS3, the most conserved pestivirus protein, elicits antibodies that are 
not strongly neutralizing but are broadly recognized (Donis et al., 1991, Bolin and 
Ridpath, 1989).  
BVDV subunit vaccines studies in cattle have focused on E2 or NS3 antigens, 
either as protein or plasmid encoding antigen DNA (Nobiron et al., 2003, Young et 
al., 2005, Thomas et al., 2009). DNA vaccination in general did not result in a robust 
immune response, whilst E2 protein on its own only conferred partial protection. The 
combination of E2 protein and the more conserved antigen, NS3, in a vaccine 
formulation has been suggested as a means to enhance protective immune responses 
against BVDV (Brownlie et al., 2010) and the evaluation of a nanoparticle vectored 
E2 and NS3 protein formulation is presented in Chapter 5. 
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There is currently discussion on whether atypical bovine pestiviruses should 
be recognized as a third BVDV species and if so, what implications this might have 
for currently licensed BVD diagnostics and vaccines as well as for the BVDV control 
programmes and eradication status of countries and regions. There is increasing 
evidence of the clinical and epidemiological relevance of these emerging viruses 
with clinical disease following experimental infection in cattle and sheep and reports 
of natural infections in Southeast Asia, South America and Europe. Antigenic 
variation between BVDV-1 and 2 species has already led to the inclusion of BVDV-
2 strains in some vaccines (Ridpath, 2005), and this needs to be considered in the 
case of atypical bovine pestiviruses. Vaccine efficacy studies should also include 
challenge with heterotypic BVDV isolates as well as novel antigenically distinct 
variants (Kapil et al., 2008). Our findings support the consideration of atypical 
bovine pestiviruses in the development of diagnostics and vaccines, as well as the 
recognition of their clinical and epidemiological relevance.  
Finally, it has been suggested that vaccines using reconstructed or 
archetypical/parental virus species or strains may be more broadly protective as the 
likelihood of conserved immune targets is greater than in viruses further down the 
evolutionary tree (Ducatez et al., 2011, Weaver et al., 2011). This is especially the 
case for RNA viruses with high mutation rates and significant genetic diversity 
(Lauring and Andino, 2010). While it is technically feasible to combine genetic 
variants of a single antigen (Liang et al., 2007), a recent influenza study has shown 
that a computationally optimized hemaglutinin-based virus-like particle (VLP) 
vaccine has better breadth of antibody and protective efficacy than a VLP containing 
a polyvalent mixture of HA proteins from multiple clades (Giles et al., 2012). Given 
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the vast amount of genetic and phylogenetic information available, a similar 
approach should be considered for future BVDV vaccines.  
In conclusion, this study highlights the impact antigenic diversity among 
bovine pestiviruses may have on both T cell and antibody responses. It is hoped that 
this work will aid in the development of more broadly efficacious vaccines, as well 
as improved diagnostics against bovine pestivirus infections. 
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5 EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF 
BIODEGRADABLE NANOPARTICLE VECTORED BOVINE VIRAL 
DIARRHOEA VIRUS ANTIGENS 
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SUMMARY 
The effectiveness of vaccination as a tool for control of BVDV has been 
hampered by inadequacies of existing vaccines. The development of subunit vaccines 
has focused on the polymorphic E2 protein, a dominant target of neutralising 
antibodies and CD4 T cell responses, with good efficacy albeit limited to 
homologous viral challenge. The inclusion of a better conserved antigen such as NS3 
protein, a target of both T cell and antibody responses, has been proposed for 
induction of broader immune responses. This study aimed to test the vaccine 
potential of E2 and NS3 antigens formulated in poly (D, L-lactic-co-glycolic acid) 
(PLGA) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C)) 
(Vaccine NP) in comparison to ovalbumin and poly(I:C) formulated in a similar 
manner (Control NP), and an inactivated BVDV vaccine (IAV). Six to eight month 
old calves (n=6 per group) were inoculated subcutaneously with each of the 
preparations, received a similar boost vaccination after three weeks, and were 
challenged with 10
6.7 
TCID50 of BVDV-1a Horton 916 after a further three weeks. 
Virus neutralizing activity and E2 specific antibodies were observed in both Vaccine 
NP and IAV groups although significant NS3 antibodies were not induced in the 
Vaccine NP group until after viral challenge. IFN-γ, MIG/CXCL9 and proliferative 
responses were observed following ex vivo PBMC stimulation with E2 and NS3 
proteins in both vaccinated groups after challenge infection. IFN-γ responses were 
also observed to the challenge virus in all groups after resolution of infection, but 
only the Vaccine NP and IAV groups responded to a divergent atypical bovine 
pestivirus, Th/04_KhonKaen. Reduced clinical symptoms and virus load were 
observed in the vaccinated groups compared to the Control NP group. While the 
protection afforded by both vaccines was not complete and the performance of the 
Vaccine NP appeared inferior to the IAV vaccine, particulate delivery of subunit 
antigen presents a customisable mode of antigen delivery that can be improved. 
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5.1 INTRODUCTION 
Bovine viral diarrhoea virus (BVDV) is an economically important pathogen 
that is endemic in cattle around the world. BVDV has a profound impact on the cattle 
industry as a result of productive and reproductive losses (Houe, 1999). The main 
strategies for the control of BVDV have included the identification and removal of 
persistently infected (PI) calves, believed to be the major reservoirs of infection, 
increased biosecurity and vaccination (Deregt, 2005). 
Vaccination plays a significant role in controlling BVDV infection, but the 
inadequacy of existing vaccines has hampered eradication efforts (Kelling, 2004). 
Modified live attenuated vaccines, although effective, have some shortcomings such 
as the requirement of cold storage and a limited shelf life, safety concerns in 
pregnant cattle, immunosuppression and possible reversion to virulence or genetic 
recombination with field viruses (van Oirschot et al., 1999). Inactivated vaccines 
whilst safer to use, require frequent immunisation and often fail to provide foetal 
protection. It has been proposed that inactivated BVDV vaccines lack efficacy 
because of their failure to induce potent T cell responses (Endsley et al., 2003). 
Collen and Morrison (2000) have further speculated that this failure is due to 
inactivated preparations lacking non-structural viral proteins that have been shown to 
be targets of the T cell responses of immune cattle. 
Attempts to develop subunit vaccines have focused on the structural envelope 
protein E2, which is a dominant target of neutralising antibodies and a target of CD4 
T cell responses (Donis et al., 1988). DNA vaccination with an E2 plasmid leads to 
neutralizing antibodies to homologous virus but not to heterologous virus prior to 
challenge (Harpin et al., 1999, Nobiron et al., 2003, Liang et al., 2005). Unlike in 
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mouse models, DNA vaccination in large animals has typically been shown to be of 
low efficacy and requires large doses to achieve strong immune responses (Brun et 
al., 2011). Vaccination using an E2 DNA prime-protein boost regime (Liang et al., 
2006) or Quil-A adjuvanted E2 protein (Thomas et al., 2009) has been shown to have 
improved efficacy, but immunity to heterologous viruses is still hampered by the 
high antigenic variability of this target (Liang et al., 2008). 
In addition to the use of adjuvants and/or cytokines such as IL-2, IL-1β and 
GM-CSF to improve E2 vaccine efficacy, the inclusion of better conserved targets 
such as non-structural viral proteins has been suggested (Reddy et al., 1993). The 
non-structural protein, NS3, is the most conserved pestivirus protein (Collett, 1992)  
and has also been considered as a BVDV vaccine candidate. The NS3 protein has 
multiple enzymatic activities (Grassmann et al., 1999) and functional constraints on 
this protein may counterbalance immunologic pressure thus allowing it to be a 
common target for T cell and antibody responses. DNA vaccination using an NS3 
expressing plasmid, however, only showed partial protection in calves (Young et al., 
2005). It has been proposed that combining recombinant E2 and NS3 protein in a 
vaccine formulation may increase the efficacy of E2 subunit vaccines and also 
improve heterologous protection by inclusion of a target of conserved responses 
(Brownlie et al., 2010).  
Biodegradable nanoparticles synthesised with innocuous polymers such as 
poly(D, L-lactic-co-glycolic acid) (PLGA) have been proposed as vehicles for the 
delivery of vaccine antigens for human and veterinary applications (Peek et al., 2008, 
Scheerlinck and Greenwood, 2006). In addition to functioning as antigen reservoirs 
and protecting antigen from degradation in the extracellular or endosomal 
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environments, particulate delivery has been reported to enhance cross-presentation of 
exogenous antigen by MHC class I molecules to CD8
+
 T cells (Shen et al., 2006). 
PLGA particles have also been shown to activate the inflammasome in antigen 
presenting cells and therefore enhance innate and adaptive responses (Sharp et al., 
2009). Furthermore, defined immunostimulatory molecules such as Toll-like receptor 
(TLR) agonists and cytokines, as well as antibodies or ligands targeting the particles 
to particular antigen-presenting cells such as dendritic cells can be rationally 
encapsulated or coated onto the surface of the nanoparticles (Elamanchili et al., 
2004). Co-delivery of TLR agonists and antigen in biodegradable nanoparticles has 
been shown to enhance both T cell and humoral responses compared to inoculation 
of soluble antigen and TLR agonists (Kasturi et al., 2011, Diwan et al., 2002). 
A variety of TLR agonists have been evaluated for their potential to adjuvant 
vaccines and of particular significance for anti-viral vaccines is polyinosinic: 
polycytidylic acid (poly(I:C)), a synthetic double stranded RNA analogue that is an 
agonist for endosomal TLR-3 and the cytosolic receptors retinoic acid inducible gene 
I (RIG-I), melanoma differentiation-associated gene 5 (MDA-5) and DNA-dependent 
protein kinase catalytic subunits (DNA-PKcs) (Meylan and Tschopp, 2006). 
Poly(I:C) is an innate inducer of  IL-12 and type I IFN thus enhancing DC 
maturation and B cell activation resulting in enhanced cross-presentation and potent 
T cell and antibody responses (Steinhagen et al., 2011). 
This study aimed to assess the immunogenicity and protective efficacy of E2 
antigen-coated PLGA nanoparticles encapsulating NS3 antigen and poly(I:C) after a  
homologous prime-boost vaccination and challenge with a BVDV field strain. 
Antigen specific T cell and antibody responses after vaccination and protection after 
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viral challenge were directly compared against those induced by a commercial 
inactivated BVDV vaccine. 
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5.2 RESULTS 
 
5.2.1 Immune responses following vaccination and challenge 
 
5.2.1.1 Antibody responses 
Six to eight month old calves (n=6 per group) were inoculated 
subcutaneously with E2 and NS3 antigens formulated in PLGA nanoparticles 
adjuvanted with poly(I:C) (Vaccine NP) in comparison to ovalbumin and poly(I:C) 
formulated in a similar manner (Control NP), and an inactivated BVDV vaccine 
(IAV). The calves received a similar boost vaccination after three weeks, and were 
challenged with 10
6.7 
TCID50 of BVDV-1a Horton 916 after a further three weeks. 
Antibody responses following vaccination and challenge were assessed by measuring 
BVDV specific antibody responses, using a commercial indirect ELISA kit, by 
assessing virus neutralization titres and by competition antibody ELISA against E2 
and NS3 proteins. BVDV specific antibody responses were determined as percent 
positivity (PP) values of serum antibody binding to plates coated with crude BVDV 
antigen (Figure 5.1a). Both the IAV and Vaccine NP groups seroconverted after the 
booster vaccination at 28 days post vaccination (28 dpv), with the IAV group having 
significantly higher responses than the Vaccine NP group up to the point of viral 
challenge (41 dpv). Following challenge, the Control NP group become antibody 
positive after two weeks (58 dpv) but antibody levels were significantly lower than 
the IAV and Vaccine NP groups. The IAV group was still significantly higher than 
the Vaccine NP group at 58 dpv.  
Virus neutralization titres (VNT) followed similar trends to that of total 
BVDV antibody, with neutralization of the challenge virus, BVDV-1a Horton 916, 
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being observed at the point of seroconversion (28 dpv) (Figure 5.1b). VNT values 
appeared higher in the IAV group compared to the Vaccine NP group prior to 
challenge and were significantly greater at 58 dpv. After challenge (58 and 65 dpv), 
VNT titres from both vaccinated groups were significantly higher than in the Control 
NP group.  
E2 and NS3 specific antibody levels were determined as percent inhibition 
(PI) values. E2 antibody values in all groups were in agreement with those observed 
by the BVDV antibody ELISA and VNT (Figure 5.2a). In contrast, NS3 antibodies 
were only observed at a level considered ‘positive’ by the assay manufacturer in the 
IAV group after the boost vaccination but not in the Vaccine NP or Control NP 
groups until two weeks after challenge (58 dpv) (Figure 5.2b). NS3 antibodies 
appeared to be mounted following boost in the Vaccine NP group but were not above 
the assay cut-off for positivity. NS3 antibody levels after challenge in the Vaccine 
NP group were lesser than in the IAV group but greater levels than in the control NP 
group. Differences in antibody levels were resolved by a two-fold serial dilution of 
pooled sera from the two vaccine groups prior to challenge (41 dpv) for E2 and after 
challenge (58 and 65 dpv) between all three groups for both E2 and NS3 antibodies. 
Prior to challenge (41 dpv), E2 antibodies in the Vaccine NP group were above the 
assay cut-off at 1/32 dilution, while the IAV group was detected at 1/64. After 
challenge, both vaccinated groups had detectable amounts of antibody up to 1/512 
with the IAV group levels significantly greater than in the Vaccine NP group at both 
58 and 65 dpv. NS3 antibodies were significantly greater in the vaccinated animals 
than the Control NP group at all dilutions tested (1/4 – 1/512) at 58 and 65 dpv, and 
greater in the IAV group than at Vaccine NP group at 1/512 at 58 dpv, and from 1/32 
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at 65 dpv (Figure 5.2c). Ovalbumin antibody responses were observed in the Control 
NP (Ovalbumin and Poly (IC) encapsulated in PLGA) group (n-6) pre-boost (21 dpv) 
and following challenge (day 42 dpv) but not pre-vaccination (0 dpv) or in the 
Vaccine NP group (Figure 5.3). 
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Figure 5.1. BVDV specific antibody responses following vaccination and challenge. 
(a) Total BVDV antibody responses determined by indirect ELISA as percent 
positivity (PP) after booster vaccination (21 dpv) and challenge (41 dpv). PP values 
greater than 10% were considered positive. Data shown as group means±SD. (b) 
Virus neutralization titres following priming (0) and booster (21 dpv) vaccination, 
and challenge (41 dpv) in the different groups shown as scatter plots with geometric 
means and 95% confidence interval. 
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Figure 5.2. E2 and NS3 specific antibody responses following vaccination and 
challenge. E2 (a)and (b) NS3 antibodies as measured by blocking ELISA and given 
as mean percent inhibition (PI) values for the different experimental groups after 
prime (0 dpv) and boost (21 dpv), and following viral challenge (41 dpv). Antibody 
levels in both assays were considered positive if greater than 30%. A two-fold 
dilution of pooled serum from the different groups was assessed for E2 antibodies (c) 
between the IAV and Vaccine NP groups at the day of challenge (41 dpv ) and 
between the three groups after challenge, at 58 dpv (17 dpc) and 65 dpv (24dpc). A 
similar dilution was assessed for NS3 antibodies (d) between the three groups at 58 
and 65 dpv. Data is shown as means±SD. 
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Figure 5.3 Ovalbumin-specific antibody responses in the control NP group. 
Ovalbumin specific antibody responses were assessed by ELISA using sera from the 
Control NP (Ovalbumin and Poly (IC) encapsulated in PLGA) group (n-6) pre-
vaccination (0 dpv),  pre-boost (21 dpv) and following challenge (day 42 dpv) . Data 
are presented as means ± SEM and statistical significance denoted by, ** (p<0.01) 
and *** (p<0.001). 
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5.2.1.2 T cell responses 
T cell responses were assessed by measuring IFN-γ, proliferation and 
MIG/CXCL9 levels following ex vivo stimulation of PBMC with the challenge virus 
or E2 and NS3 proteins. IFN-γ and proliferation were measured as they are 
established markers of T cell responses. MIG/CXCL9 was selected as it has been 
reported to be a monokine induced by IFN-γ that serves as an amplified and 
functional measure of the IFN-γ response (Berthoud et al., 2009). IFN-γ was secreted 
at significant levels following virus stimulation after challenge in both of the 
vaccinated groups. The IAV group had significant responses from 51 dpv (10 dpc), 
while significant responses were not observed in the Vaccine NP group until 61 dpv 
(20 dpc) (Figure 5.4a). The Control NP animals did not exhibit significant IFN-γ 
responses to the virus in this time-frame. IFN-γ responses to E2 protein followed 
similar trends with significant responses observed in both vaccinated groups from 10 
dpc, while the control animals did not appear to mount any response (Figure 5.4b). 
Responses to NS3 on the other hand were observed to significant levels in the IAV 
group following boost vaccination (28 dpv) and following challenge (44 dpv/3 dpc) 
(Figure 5.4c). Significant NS3 responses in the Vaccine NP were only observed after 
51 dpv/10 dpc) but not in the Control NP group. 
After resolution of infection (65 dpv/24 dpc), IFN-γ, MIG/CXCL9 and 
proliferative responses were assessed following ex vivo stimulation of PBMC with 
virus or proteins. IFN-γ was secreted at significant levels in response to both E2 and 
NS3 protein in the Vaccine NP group and with higher means in the IAV group but 
with no statistical significance compared to the Control NP group (Figure 5.5a). 
Whilst some proliferative responses were observed to both proteins in the IAV 
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group, these responses were only significant in the Vaccine NP group (Figure 5.5b). 
By this time point, IFN-γ responses to the challenge virus were observed in all three 
experimental groups, with trends towards lesser magnitude responses in the IAV 
group but without statistical significance (Figure 5.5c). Responses to an atypical 
bovine pestivirus, however, were significantly greater in the Vaccine NP group 
compared to the Control NP group. MIG responses were observed in all the groups in 
response to the challenge virus, but only in the IAV and Vaccine NP groups 
following stimulation with E2 and NS3 protein (Figure 5.5d).  T cell responses to 
ovalbumin were not observed. 
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Figure 5.4. Longitudinal IFN-γ responses following vaccination and challenge. Antigen specific PBMC IFN-γ responses following 
stimulation with BVDV-1a Horton 916 virus (a), E2 (b) and NS3 (c) proteins were measured by ELISA and adjusted for mock (uninfected 
cell culture cryolysate) stimulated or media background responses. Data represented as means ± SEM and statistical significance is denoted by 
** (p<0.01), *** (p<0.001) and **** (p<0.0001). N=6 per group. 
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Figure 5.5. T cell responses after resolution of viral challenge infection. (a) IFN-γ 
responses and (b) proliferative responses following ex vivo stimulation of PBMC 
with E2 and NS3 proteins at 65 dpv (24 dpc) (c) Ex vivo responses following 
stimulation with the challenge virus (Ho916) or a genetically divergent atypical 
bovine Pestivirus, Th/04_KhonKaen (TKK). (d) MIG/CXCL9 responses in pooled 
supernatants from the different groups stimulated with Ho916 virus, E2 or NS3 
proteins. All stimulations were performed in triplicate in the individual animals (n=6 
per group) apart from the MIG ELISA which was used duplicate wells of pooled 
group samples. Data represented as means ± SEM and statistical significance is 
denoted by * (p<0.05), ** (p<0.01), *** (p<0.001) and **** (p<0.0001). 
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5.2.2 Outcome of viral challenge 
 
5.2.2.1 Clinical scoring, temperatures and haematological parameters 
All the animals in the three experimental groups were challenged by 
intranasal inoculation with 10
6.7 
TCID50 of BVDV-1a Horton 916 virus. The clinical 
picture observed following challenge was mild with relatively few signs and 
symptoms observed between 3 and 10 dpc (Table 5.1). Three out of six animals in 
the Control NP group experienced mild signs of disease ranging from coughing, 
nasal and ocular discharge, and with evidence of diarrhoea in the pen. Nasal and 
ocular discharge were observed as distinct clinical signs in two different control 
animals between 8 and 10 dpc. Slightly altered ocular discharge was observed in one 
out of six animals in the IAV group. Diarrhoea was observed as a distinct clinical 
sign in one out six animals in the Vaccine NP group while another animal was 
observed to have persistent diarrhoea prior to viral challenge. No significant 
differences in weight gain were observed between the groups following vaccination 
and challenge. Mild transient pyrexia (rectal temperature above 40°C) was observed 
in all the groups after viral challenge (Figure 5.6a). One of the Control NP animals 
had an elevated temperature (40.6°C) at 2 dpc, while a number of animals from each 
group had fever between 7 and 8 dpc. Fewer animals in the IAV group had rectal 
temperatures above the normal range (38.6 ±1.6°C) with mean temperatures 
significantly lower than in the Control NP and Vaccine NP groups at 7 dpc. Three 
out of six animals in the Vaccine NP group had fever at both 7 and 8 dpc, while only 
one and three animals had fever at 7 and 8 dpc, respectively in both the Control NP 
and IAV groups. 
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Transient leukopoenia (Figure 5.6b) was also observed between 3 and 8 dpc 
in all the groups, with mean leukocyte counts in the IAV group being significantly 
greater than in the in the Control NP group at 8 dpc. Thrombocytopenia (Figure 
5.6c) was observed in all groups around 3 dpc with no significant differences 
between groups. Differential cell counts were also assessed by flow cytometry 
following gating of leukocyte subpopulations on the basis of CD45 staining and 
differences in side scatter. Lymphocytopenia mirroring the general decrease in 
leukocytes numbers was observed in all groups without any significant differences in 
the means (Figure 5.7a). Monocytes exhibited a slight increase in number (Figure 
5.7b), while neutrophils exhibited an initial slight decrease followed by a sharp 
increase in number at 8 dpi, which was greater in the IAV and Vaccine NP groups 
relative to the Control NP group, albeit with no statistical significance (Figure 5.7c). 
A transient decrease in the number of eosinophils was also observed in all the groups 
(Figure 5.7d). The reference normal range of the different populations are shown as 
suggested in Schalm’s Veterinary Haematology for 6 months old cattle (Weiss and 
Wardrop, 2010). 
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Table 5.1. Clinical scores after BVDV challenge 
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Figure 5.6. Rectal temperatures and haematological parameters following BVDV 
challenge. (a) Mean rectal temperatures in experimental animals following challenge. 
Horizontal dotted lines denote normal temperature range while the solid line denotes 
fever. (b) Leukocyte and (c) platelet counts following BVDV challenge. Data shown 
as  group means ± SD. Horizontal dotted lines denote normal cell count range  while 
the solid line denotes the average (Weiss and Wardrop, 2010). 
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Figure 5.7. Differential leukocyte counts following BVDV challenge. Changes in (a) 
lymphocytes, (b) monocytes, (c) neutrophils and (d) eosinophils in peripheral blood 
following BVDV challenge as assessed by flow cytometry. Data shown as group 
means±SD. Solid horizontal lines indicate approximate normal values while the 
dotted lines indicate the normal range for the respective populations (Weiss and 
Wardrop, 2010).  
5. Evaluation of a nanoparticulate BVDV subunit vaccine 
 
112 
 
5.2.2.2 Detection of viral antigen and nucleic acid 
BVDV antigen was detected by E
rns
 antigen ELISA (Figure 5.8a). Viral 
antigen above the assay cut-off for positivity (0.3) was detected in the Control NP 
and Vaccine NP groups between 6 and 8 dpc. Mean values of the viral antigen were 
significantly less in both the IAV and Vaccine NP groups compared to the Control 
NP group, and less in the IAV compared to the Vaccine NP group at both time 
points.  Detection of viral RNA by qRT-PCR (Figure 5.8b) mirrored antigen levels 
with viral RNA being detected in the Control NP group between 3 and 20 dpc and 
significantly greater levels observed at 9 dpc compared to the two vaccinated groups. 
The duration in which viral RNA was detected was shorter in the IAV and Vaccine 
NP groups (up to 13 dpc and 15 dpc, respectively). 
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Figure 5.8 Detection of viral antigen and nucleic acid following challenge with 
BVDV-1a Horton 916. (a) BVDV E
rns
 antigen detection in blood by ELISA. The 
dotted line shows the assay cut off for antigen positivity (COD>0.3). (b) Viral RNA 
as quantified by qRT-PCR shown as equivalent TCID50 values. The dotted line 
shows the lower detection limit (10
0.55 
TCID50). Data shown as means±SD and 
statistical significance is denoted by * (p<0.05), ** (p<0.01) and *** (p<0.001) 
compared to the control group. 
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5.3 DISCUSSION 
This study aimed to evaluate vaccination with recombinant BVDV antigens, 
E2 and NS3 in a poly(I:C) adjuvanted PLGA nanoparticle formulation compared to a 
commercial inactivated vaccine. Antibody responses as detected by antigen capture 
ELISA and virus neutralization titres (VNT) were detected in both vaccine 
preparations after boost inoculation and at higher levels than the control animals after 
viral challenge. Higher levels of total BVDV specific antibody were observed in the 
inactivated vaccine group than the E2 and NS3 protein vaccinated animals, possibly 
due to the presence of antibody to other BVDV antigens such as E
rns
 in the former. 
E2 antibodies in the vaccinated animals, and in the control animals after challenge, 
were highly correlated with VNT as expected (Deregt et al., 1998).  
In contrast to the to the inactivated virus vaccine, significant levels of NS3 
antibodies were not detected after vaccination with the E2 and NS3 nanoparticulate 
formulation but were detected to higher levels compared to the control animals 
following BVDV challenge. To rule out a limited detection of antibody to the NS3 
helicase in the competition ELISA, an antigen-capture ELISA was setup with the 
helicase antigen and the antibodies used in the commercial kit. It was confirmed that 
these antibodies were able to recognize and therefore compete with serum antibody 
against the NS3 helicase domain. The lack of a strong antibody response against 
encapsulated NS3 antigen is interesting since antibody responses to ovalbumin were 
detected in control animals vaccinated with an equivalent quantity of encapsulated 
antigen. It may be speculated that the dose of NS3 administered, although equivalent 
to ovalbumin, was not sufficient to elicit a robust antibody response, or there may 
have been a loss of conformation of NS3 protein due to E. coli expression or during 
nanoparticulate formulation. 
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Partial E2 and NS3 antigens were used in this study for practical purposes, 
primarily ease of expression. The E2 antigen was without the C terminus that 
includes 30 hydrophobic amino acids, which could function as a transmembrane 
anchor for E2. It is therefore able to be secreted from cells that express it unlike the 
full length protein which remains cell associated (Rumenapf et al., 1993). The NS3 
protein consisted of the C-terminal helicase region without the protease domain that 
has been shown to induce apoptosis related to increased caspase activity (St-Louis et 
al., 2005, Gamlen et al., 2010). These partial proteins however, have been previously 
shown to be the target of both T cell and antibody responses (Paton et al., 1992, 
Deregt et al., 2005, Collen et al., 2002). Whilst the use of partial-length proteins is 
justified for practical purposes, it may be important to express and evaluate responses 
to full-length antigens in the future.  
In this study, T cell responses were also observed in animals vaccinated with 
the inactivated vaccine and the BVDV subunit nanoparticulate formulation. IFN-γ 
responses to NS3 were detected in the inactivated vaccine before viral challenge, 
while responses to E2 and the challenge virus were found to be more robust than in 
the control animals following BVDV challenge. After challenge and resolution of 
infection, the nanoparticulate vaccine group appear to mount better IFN-γ, monokine 
induced by gamma (MIG/CXCL9) and proliferative responses than observed in the 
inactivated vaccine group. Better proliferative responses to the nanoparticulate 
vaccine may hint at improved central memory responses, while MIG/CXCL9 
responses are associated with vaccine-induced T cell responses (Berthoud et al., 
2009). Responses to the challenge virus were detected in all groups by 24 dpc, 
although responses to an atypical bovine Pestivirus, Th/04_KhonKaen, were detected 
to a greater level in the nanoparticulate vaccine and inactivated vaccine groups 
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compared to the control group perhaps indicating a better quality response which 
may be more broadly protective. T cell responses to ovalbumin were not detected in 
this study but have been reported previously following vaccination of cattle with 
ovalbumin in IFA (Nonnecke et al., 2012).  
While antibody responses to the nanoparticle formulation were observed to be 
inferior to the inactivated vaccine, the advantage of this method of delivery is that it 
is highly adaptable with scope for improvement. Responses may be enhanced by use 
of better adjuvants or combinations of adjuvants that stimulate broader immune 
responses. Also, combinations of TLR agonists may act synergistically in triggering 
the desired T cell or humoral immune responses (Napolitani et al., 2005) A recent 
study, demonstrated enhanced antibody responses to synthetic nanoparticles 
containing antigen and TLR-4 and TLR-7 ligands compared to nanoparticles 
containing antigen and individual TLR ligands (Kasturi et al., 2011). Another 
consideration for enhanced responses would be the use of a heterologous prime-boost 
regime. An E2 DNA/protein prime/boost strategy has shown enhanced 
immunogenicity and efficacy compared to homologous prime and boost with the 
protein or DNA constructs (Liang et al., 2006). 
Neither the E2 and NS3 nanoparticulate formulation nor the inactivated virus 
vaccines evaluated in this study were able to confer sterile immunity. However, 
decreases in viral load (both peak and duration of viraemia), as shown by decrease in 
both viral antigen and RNA, as well as reduced clinical scores in both vaccinated 
groups were evidence of a degree of protection. Nevertheless, no significant 
differences in haematological parameters or rectal temperatures were observed 
between the vaccinated and control groups. The failure of vaccination to prevent 
transient leukopenia associated with BVD may be disadvantageous to the animal in 
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spite of recovery from acute infection as this is thought to render animals susceptible 
to secondary pathogens (Bolin, 2002). 
The transient leucopoenia and elevated rectal temperature appear to be a 
hallmark of an innate mechanism of post-challenge virological control and not 
necessarily a consequence of virus induced pathology. It is thought that that these 
responses play a role in virus clearance in addition to pre-existing adaptive responses 
in the vaccinated animals, and in the control animals, albeit, after a longer period 
which may present a chance to shed and transmit virus to other naïve animals. The 
transient leucopoenia associated with early viral infection has been shown to be 
dependent on type I IFN receptor signaling. Type I IFN (α/β) responses to viral 
infection or treatment with TLR agonists poly(I:C) and resiquimod (R-848) have 
been shown to cause lymphopenia by regulating lymphocyte recirculation (Kamphuis 
et al., 2006). Early IFN-α and γ responses have been shown to be induced following 
infection with noncytopathic BVDV (Charleston et al., 2002) and it is possible that 
the early transient leucopoenia may be associated with secretion of these cytokines in 
response to viral infection. 
Elevated temperatures in this study were also shown to coincide with the 
transient increase in neutrophils. Interestingly, the vaccinated animals, which control 
the virus better, appear to have higher levels of neutrophils than the control animals. 
A similar transient increase in neutrophils after viral challenge that is enhanced in 
vaccinated animals has been observed following an E2 DNA-prime, protein-boost 
vaccination and BVDV-1 and -2 challenge (Liang et al., 2008). Neutrophils play an 
important role in virus control and their function is found to be suppressed in cattle 
persistently infected with BVDV, an observation that was reversed by treatment with 
recombinant IFN-α and γ (Brown et al., 1991, Steinbeck and Roth, 1989). It may be 
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speculated that the reduced viral load in the vaccinated animals unmasks this 
suppression resulting in a transient neutrophilia which may aid in clearance of the 
virus. 
Acute BVDV type I infection, which represent the majority of BVDV 
infections, results in mild disease of short duration characterized by fever, increased 
respiratory rate, diarrhoea and leukopenia (Baker, 1995). The challenge virus used in 
this study, BVDV-1 strain Horton 916, was associated with severe fatal disease in the 
field and has been previously used in an experimental infection at a titer of 10
6.7 
TCID50 with mild clinical disease and leucopoenia (Rebecca Strong, APHA, personal 
communication). The reproduction of symptomatic acute BVDV infection in 
immunocompetent animals by experimental intranasal challenge is difficult, even in 
the case of virulent field viruses, and better challenge models need to be explored.  
Bovidec®, the inactivated vaccine in this study, is used for active 
immunisation of female breeding cattle to prevent transplacental infection, and in 
calves from 4 months of age (after the decline of maternal antibody) to prevent 
viraemia and viral shedding. Systemic vaccination with Bovidec has been shown to 
protect against respiratory challenge (Howard et al., 1994) and against foetal 
infection (Brownlie et al., 1995). Whilst somewhat lesser responses were observed to 
the nanoparticulate formulation in this study, similarities in induction of neutralizing 
antibody and T cell reactivity makes this means of delivering subunit antigens a 
prospect worthy of improvement.  
In conclusion, whilst the inactivated vaccine performed better in this study, 
the nanoparticulate vaccine formulation offers a promising mode of vaccination that 
can be improved by use of better adjuvants, greater consideration on location of 
antigen (coated or encapsulated), as well as targeted delivery of antigen and adjuvant 
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to dendritic cells. In addition to the adaptability of this method of antigen delivery, 
other advantages such as the relative safety and capacity for differentiating infected 
from vaccinated animals (DIVA) are offered by the use of subunit antigens. It is 
hoped that the data generated will inform the design of improved vaccines against 
BVD.  
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An understanding of the immune responses that contribute to protection is 
critical to a rational approach to vaccine development, and involves an empirical 
evaluation of the immune mechanisms induced by infection or vaccination.  This 
includes an appreciation of the main antigenic targets, the phenotype, functional 
mechanisms and kinetics of these responses. Effective vaccines have been shown to 
elicit antigen-specific antibody responses by plasma cells, as well as both B cell and 
T cell memory responses (Amanna and Slifka, 2011). This study endeavoured to 
generate data on T cell responses to viral proteins and utilize this for the design of a 
subunit antigen vaccine against BVDV. 
The first part of the study aimed to rationally identify the main targets of T 
cell responses to BVDV by screening synthetic peptides representing the BVDV 
proteome. While a number of proteins have been shown to be targets of CD4 
responses (Collen and Morrison, 2000), no systematic study has been conducted to 
assess responses to all proteins simultaneously. In this study, we attempted to 
characterize T cell responses to BVDV by assessing IFN-γ responses to synthetic 
overlapping peptide pools representing the different viral proteins and spanning the 
BVDV proteome. A similar approach has previously been utilized in the case of 
related CSFV in pigs with a peptide library representing 82% of the proteome 
(Armengol et al., 2002). In that study, proliferative and IFN-γ responses were 
observed to a number of peptides on the E
rns
, E1, E2 , NS2-3, NS4A, NS4B and 
NS5A proteins, with a CSFV specific CD8
+
 cytotoxic T lymphocyte (CTL) and a 
helper T cell epitope identified on NS2-3 protein. 
This work was largely limited to assessing immune responses to peptide 
pools representing individual BVDV proteins with no significant attempt to define 
individual antigenic peptides. This was primarily due to the limited number of 
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animals (four) and also, the minimal knowledge of the MHC-II haplotypes of the 
animals. A single CD4 antigenic peptide was mapped on E2 protein for exploratory 
purposes. Interestingly, only a few viral CTL epitopes have been mapped in cattle, 
which were identified from the foot and mouth disease virus (FMDV) (Guzman et 
al., 2008), indicating that this is an aspect that needs further exploration to generate 
more detailed data. CTL epitopes have also been successfully mapped using 
synthetic peptides against visna/maedi virus in sheep following infection and a DNA-
prime-MVA-boost vaccination (Wu et al., 2008). To date, the development of 
vaccines against rapidly evolving RNA viruses and other complex pathogens using 
synthetic peptides has not been fruitful due to poor immunogenicity as a result of 
immune escape caused by mutation. The MHC restricted nature of these responses 
and the potential antigenic polymorphism of these targets between different strains 
are further drawbacks to such a reductionist approach (Naz and Dabir, 2007). 
However, definition of T cell epitopes allows the development of tools such as MHC 
glycoprotein-peptide tetramers (Altman et al., 1996) which may be of use in better 
characterizing responses following infection and/or vaccination. Also, more recently, 
regulatory or pathogenic epitopes have been described whose exclusion from vaccine 
antigens can increase their efficacy (Welsh and Fujinami, 2007).  
The proper mapping and definition of specificities and MHC restriction of 
antigenic determinants/epitopes often requires MHC homozygous animals or at the 
very least, MHC defined animals which requires the capacity for molecular 
characterization of both MHC class I and II alleles (Collen et al., 2002). Also, tools 
such as homologous transformed antigen presenting cells (Hart et al., 2011a), antigen 
specific T cell lines (Glass and Spooner, 1990) and xenogeneic antigen presenting 
cell lines transfected with single MHC alleles (Gaddum et al., 1996a) can be useful 
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for the determination of the fine specificity of T cell responses. Computational 
prediction of epitopes to bovine pathogens has been aided by definition of peptide 
binding patterns/motifs (Hegde et al., 1995, Bamford et al., 1995, Gaddum et al., 
1996b) as well as the development of a bovine leukocyte antigen (BoLA) epitope 
mapping algorithm/matrix (De Groot et al., 2003b, De Groot et al., 2003a). An 
attempt at computational prediction of bovine MHC class I restricted CTL BVDV 
epitopes has been made, although none of the candidate epitopes have been validated 
to date (Srikumaran and Hegde, 1997).  
The second part of this study looked at the effect of genetic and antigenic 
diversity, and the emergence of new variant viruses on immune responses, which 
may have consequences for the efficacy of vaccination programmes. Evolutionary 
changes in BVDV are responsible for emergence of genetic and antigenic diversity 
(Goens, 2002). This has so far lead to the emergence of two recognized BVDV 
species as well as a third putative species, and numerous subgenotypes within the 
species. Evidence of positive selection on BVDV E2 glycoprotein has been observed, 
that may be driven by immune pressure or host tropism (Tang and Zhang, 2007). 
While surface antigens are likely to be subject to the most variability as a result of 
immune pressure as well as host and cell tropism, non-structural proteins are likely to 
be better conserved as a result of the limited exposure. Various non-structural 
proteins, such as BVDV NS3, have been shown to be targets of immune responses 
that may contribute to protection. It was, therefore, hypothesised that combination of 
NS3 with the immunodominant surface glycoprotein E2 would enhance the efficacy 
of subunit vaccines and reduce the likelihood of immune escape as a result of the 
antigenic diversity observed to the latter antigen.  While the antigenic closeness of 
vaccine and prevalent field viruses may be crucial for vaccine efficacy, heterogeneity 
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from previously encountered strains may aid avoidance of ‘original antigenic sin’ 
(Francis, 1960), a phenomenon in which a secondary response is focused to only the 
cross-reactive targets in the primary exposure, which may aid immune escape 
(Lambert et al., 2005). The possible effect of previous exposure or vaccination will 
also need to be explored in vaccination against BVDV. This study showed that the 
extent of cross-reactivity varies between antigens depending on the degree of 
conservation across different virus strains. Selection of conserved antigens may, 
therefore, overcome possible interference due to pre-exposure to variant antigens, as 
well as provide cross-protection.  
The final part of this study looked to assess the immunogenicity of selected 
BVDV antigens, E2 and NS3, in a vaccination and challenge study. While the PLGA 
nanoparticles delivery model proved promising, questions remain regarding the 
dosage and quality of the antigen used, as well as the choice of adjuvant. The 
importance of antigen quantity in a vaccine dose for efficacy is known for E2 
(Bruschke et al., 1997, Thomas et al., 2009) but is yet to be reported for NS3. The 
means of expression of recombinant protein is crucial, as it will determine both the 
quantity required and antigenic authenticity of the protein. While functional 
authenticity may not be critical for T cell responses and linear B cell epitopes, B cell 
recognition of conformational epitopes will rely on the protein being produced as 
close to its native structure as possible. The choice of expression system has 
traditionally relied on convenience, yield and functional authenticity. In addition to 
high yields, baculovirus insect cell expression produces proteins with similar post-
translational modification to mammalian cells. However, it has been shown that 
mammalian expressed E2 protein is required at considerably lesser quantities than 
baculovirus expressed protein to elicit comparable immune responses and protection 
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from viral challenge (Thomas et al., 2009). The loss of glycosylation sites on CSFV 
E2 and E
rns
 baculovirus derived proteins has been shown to affect antibody responses 
but not necessarily protection from lethal challenge suggesting that T cell responses 
may contribute significantly to this (Gavrilov et al., 2011). Interestingly, truncated 
E2 protein expressed in cultivated tobacco (Nicotiana tabacum) plants to avoid 
animal contaminants has been tested successfully for antigenicity and 
immunogenicity in guinea pigs and is being considered as a next generation vaccine 
(Nelson et al., 2012). The performance of E. coli derived NS3 in our study appears to 
result in inferior antibody responses compared to native NS3 contained in the 
inactivated vaccine preparation suggesting that antigenic authenticity may be just as 
important for antibody responses to non-structural proteins. 
A number of BVDV vaccine studies have been conducted in mice, cotton 
rats, guinea pigs and other models (Chase et al., 2004). The selection of appropriate 
models however needs better consideration. Sheep, which are also susceptible to 
BVDV infection, are suitable models in vaccination studies but like in cattle, care has 
to be taken to ensure that they are border disease virus (BDV) free prior to challenge. 
Correlations have been established between bovine, and ovine and guinea pig models 
following the evaluation of the immunogenicity of experimental vaccines 
concurrently (Fernandez et al., 2009). Subsequently, immunogenicity of an E2 
subunit vaccine has been determined in guinea pigs on the basis of the association 
found between responses in this experimental model and the natural bovine host 
(Pecora et al., 2012). Prevention of foetal infection is considered to be the gold 
standard for BVDV vaccines, but it is not a rational model for primary 
immunogenicity and efficacy testing. Systemic multiple site inoculation of calves, 
albeit artificial has been shown to induce more overt clinical disease than traditional 
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respiratory (intranasal) challenge (Polak and Zmudzinski, 2000) and may be a useful 
modification to current viral challenge protocols. Another challenge model that could 
be explored could be transmission via in-contact persistently infected animals which 
is a likelier mode of transmission in herds than via transiently infected animals 
(Thurmond, 2008). 
Modified live virus vaccines, although reported to cause transient 
leukopoenia after inoculation, are thought to stimulate better T cell and antibody 
responses than inactivated vaccines and hence confer sterile protection with no 
viraemia, fever or haematological changes observed after challenge (Fulton, 2008).  
While we were unable to assess immune responses to a modified live vaccine in this 
study, this would be the ideal comparison, as this appears to be the gold standard of 
vaccination, albeit with significant safety concerns.  
T cells have been shown to play a significant role in adaptive immune 
responses to infectious diseases including BVDV and it is important to have an 
understanding of the phenotype and function that are reflective of effective T cell 
responses. This will involve assessing the quantity and quality, as well as the 
kinetics/synchrony of immune responses and the effect on memory and protection 
(Seder et al., 2008, Pantaleo and Harari, 2006). The need for broader, more in-depth 
evaluation of immune responses to BVDV vaccines has been recognized. Reber et. 
al. (2006) measured VNTs, lymphocyte proliferation, cytokine mRNA expression, 
intracellular cytokine production and release of IFN-γ following vaccination with 
modified live or killed BVDV vaccines. More in-depth analyses, however, have not 
been conducted to characterize the specificity and phenotype of T cell responses to 
BVDV.  Different CD4 T cell memory populations have been previously described 
on the basis of CD45RO, CD62L and CCR7 staining in cattle (Totte et al., 2010). 
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Bovine antigen specific memory CD8
+
 cells induced by BCG in cattle have also been 
defined as CD45RO
+
 (Hogg et al., 2009). Furthermore, protocols for the 
identification of polyfunctional bovine T cells populations by intracellular detection 
of IL-2, TNF-α and IFN-γ have recently been published (Whelan et al., 2011) and 
could be utilised in the assessment of vaccine induced responses. Secretion of other 
cytokines such as MIP-1β and functions such as proliferation, cytotoxic activity 
(direct killing, degranulation or perforin expression) are also crucial in characterizing 
the functional profile of T cells.  
An alternative read out for immunogenicity is monokine induced by gamma 
(MIG/CXCL9). MIG is an inflammatory chemokine secreted primarily by CD14
+
 
monocytes and macrophages, as well as neutrophils, B cells and eosinophils that is 
induced by IFN-γ (Whiting et al., 2004). MIG is important in the recruitment of 
activated T cells to the site of infection, and serves as an amplified (more sensitive) 
and functional measure of IFN-γ activity (Berthoud et al., 2009). The availability of a 
bovine MIG assay used in this study can be further exploited to better characterize 
vaccine-induced responses. In this study, MIG proved to be a robust readout 
comparable to IFN-gamma, and therefore a useful tool in the assessment of T cell 
responses to BVDV and to other bovine pathogens/vaccines. 
The measurement of antibody responses has traditionally been the principle 
way of assessing immune responses to BVDV. Conventional BVDV antibody 
ELISAs are based on crude antigen prepared from BVDV infected cells usually by 
treatment with detergents and other inactivation reagents that may interfere with the 
native antigen structure.  The use of recombinant antigens expressed in bacterial or 
eukaryotic systems provides an alternative, albeit more expensive, source of antigen 
for testing for BVDV specific antibodies in serum. These enable the discrimination 
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of antibodies against different virus proteins (Chimeno Zoth and Taboga, 2006) and 
in the case of subunit or marker vaccines, may enable differentiation between 
infected and vaccinated animals (DIVA) (van Oirschot, 1999). Furthermore, other 
means of assessing antibody responses need to be applied in monitoring humoral 
responses to BVDV. While neutralizing antibodies are seen primarily to E2 protein, 
non-neutralizing antibodies are elicited to other targets such as E
rns
, E1 and NS23 
that may also be protective. A number of alternative assays may be applied to dissect 
other aspects of antibody responses such as affinity, avidity, complement activity, 
antibody-dependent cellular cytotoxicity or cell mediated virus inhibition 
(ADCC/ADCVI) (Baum, 2010). There is also a need to distinguish long-lasting 
antibody-secreting plasma cells that constitute protective memory responses with 
long lived reactive memory B cells that are triggered in response to recurrent 
antigenic challenge (Dorner and Radbruch, 2007).   
Innate immune responses to pathogens are known to shape the magnitude, 
quality and durability of adaptive responses capable of eliminating infection and 
conferring long term protective immunity (Pulendran and Ahmed, 2006). Adjuvants 
including agonists for pattern recognition receptors such as TLR ligands are known 
to activate innate immunity and create the right environment for robust adaptive 
responses. In humans, PolyICLC, an RNase-resistant analogue of Poly(I:C) 
stabilized with poly-lysine, has been shown to induce expression of genes encoding 
TLR7 and TLR4, the RIG-I and MDA-5 viral sensors, transcriptional factors 
involved in type I IFN responses (IRF7, IRF5 and IRF1) in a similar fashion to a 
protective replication-competent viral vaccine in vivo (Caskey et al., 2011). Live 
viral vaccines however, induce broader responses, an effect that could perhaps be 
mimicked by the combination of multiple adjuvants.  It is possible that the 
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nanoparticulate formulation assessed in this study may be improved by testing with 
more potent adjuvants to elicit the desired responses.  
It is also important to establish absolute or relative quantities of an immune 
response as strongly associated with a desired outcome (correlates of protection) or 
suitable in vitro surrogates that could be employed to measure vaccine efficacy (Qin 
et al., 2007). Predictive correlates of vaccine efficacy are important in vaccine 
development as they could partially eliminate the need for elaborate and costly 
vaccination and challenge studies. For this purpose, highly precise immunological 
assays and empirical validation of these correlates are necessary. In vitro surrogate 
tests may also suffice as predictors of protection by vaccination if the correlates of 
protection are unknown or difficult to measure. While both T and B cell responses 
have been shown to contribute to protective immunity against BVDV, specific 
correlates of protection have not been defined. The establishment of such correlates 
may require studies of natural infection, vaccination trials or experimental infection 
in cattle or relevant animal models (Amanna and Slifka, 2011). It is well established 
that the presence of neutralizing antibody in blood correlates with protection afforded 
by BVDV vaccination and thus serum antibody titres are a useful indicator of 
vaccine efficacy. (Saliki and Dubovi, 2004). However, no definitive quantitative 
correlate of protection has been described. Following experimental infection with a 
highly virulent BVDV-2 strain, virus neutralizing titres of 256 or less were shown 
not to protect from fever and systemic virus spread, while calves with titres lower 
than 16 developed clinically severe disease (Bolin and Ridpath, 1989). A second 
study showed that titres up to 64 were unable to protect from transmission of BVDV-
1b following exposure to persistently infected calves (Fulton et al., 2005). Titres 
required to confer cross protective virus neutralization between BVDV genotypes 
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have not been established, but titres following vaccination with inactivated BVDV-
1a and 2a were shown not to be able to protect against infection with BVDV-1b 
(Grooms et al., 2007). While our study did not attempt to establish any correlates of 
protection, this should be viewed as a critical aspect of assessment of existing 
vaccines and development of improved vaccines.  
Finally, systems biology approaches could be employed to better characterise 
responses following BVDV infection or vaccination.  BVDV has also been shown to 
differentially modulate toll-like receptors, cytokines and co-stimulatory molecule 
gene expression by RT-qPCR (Lee et al., 2008). A proteomics/mass spectroscopy 
approach revealed that the expression of proteins related to antigen presentation (Lee 
et al., 2009) and protein kinases involved in anti-viral mechanisms are modulated in 
BVDV infected monocytes (Pinchuk et al., 2008). Microarrays have also been used 
to differentiate the effects of infection with cp and ncp BVDV (Werling et al., 2005). 
A global approach may be useful in providing a better understanding of immune 
responses following infection and vaccination and therefore accelerate vaccine 
development by identifying predictors of immunogenicity and previously unknown 
mechanisms that underlie protective responses (Trautmann and Sekaly, 2011).   
It is hoped that the data generated in this study will provide a background for 
the better understanding of immune responses to BVDV and in the development of 
improved vaccines to support control and eradication. In summary, we have outlined 
a proteome-wide method of screening and selecting vaccine candidate T cell 
antigens, assessment of the extent of cross-reactivity by the defined antigens, and 
evaluated a formulation of these antigens in vivo in comparison to an existing 
vaccine.  We hope that lessons learnt in the course of this study, and discussion 
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points arising from it will aid in the advancement of rational vaccine development 
strategies to aid BVDV control and eradication. 
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APPENDIX A: PUBLICATIONS 
Kinetics of single and dual infection of calves with an Asian atypical bovine 
Pestivirus and a highly virulent strain of bovine viral diarrhoea virus 1  
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MEETINGS AND PRESENTATIONS 
5
th
 Annual Epizone (European Network of Excellence of Epizootic Disease 
Diagnosis and Control) Meeting, Arnhem, The Netherlands – 11th - 14th April 2011 - 
Oral presentation (IC 6.8 project meeting) and Poster presentation (cited) 
Festival of Research, University of Surrey, Guildford, Surrey, UK – 5th July 2011 - 
Poster presentation  
Festival of Research, University of Surrey, Guildford, Surrey, UK – 6th July 2010 - 
Poster Presentation (Received best poster prize in Infection and Immunity theme) 
5
th
 ENII EFIS/EJI Summer School in Advanced Immunology, Capo Caccia, 
Sardinia, Italy. – 9th -16th May 2010 - Poster presentation 
Research Student Day, Royal Dick School of Veterinary Studies, R (D) SVS, 
University of Edinburgh, Edinburgh – 1st April 2009 – Poster presentation  
 
TRAINING COURSES AND WORKSHOPS 
The Viva Examination, Postgraduate Skills Development Programme (PGSDP), 
University of Surrey, 20
th
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Project Management course, Wagenigen Business School, Amsterdam, The 
Netherlands - 27
th
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Epizone Short Term Mission, National Veterinary Institute, Puławy, Poland, 16th 
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Getting Published, PGSDP, University of Surrey, 21
st
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5
th
 ENII EFIS/EJI Summer School in Advanced Immunology, Capo Caccia, 
Sardinia, Italy. – 9th -16th May 2010 
Academic Writing: Reporting on Your Progress, PGSDP, University of Surrey, 9
th 
March 2010 
PhD Project Management, ULearn, University of Surrey, March 2010 
Good Practice in PhD Research , College of Medicine and Veterinary Medicine, 
University of Edinburgh, March 2009 
Postgraduate Essentials, Transkills, University of Edinburgh, October 2008 
 
